baricitinib vs tofacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: JAK · full Rheumatoid Arthritis pipeline

baricitinib · Olumiant

Marketed by Eli Lilly and partners

Approved in Rheumatoid Arthritissmall molecule
Reliable signal

NCT01710358 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.

Next expected readout: March 2027 · NCT04870203 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12): ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) (met)

Result source: NCT02265705

tofacitinib · Xeljanz

Marketed by Pfizer

Approved in Rheumatoid ArthritisSmall molecule (pan-JAK inhibitor)
Weak signal

NCT01262118 · Phase 1 · completed

This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.

Next expected readout: January 2027 · NCT06945666 (registry estimate)

Reported efficacy

High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6: HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. (not_applicable)

Result source: NCT01262118

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbaricitinibtofacitinib
ACR2061.7% vs 39.5%+22.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • 55.4% vs 27.3% 4 mg · wk 12 · n 177 · Phase 3 · primary NCT01721044
  • 65.9% vs 39.5% 2 mg · wk 12 · n 229 · Phase 3 · primary NCT01721057
  • 69.6% vs 40.2% wk 12 · n 487 · Phase 3 · primary NCT01710358
  • 58.6% vs 28.3% wk 12 · n 145 · Phase 3 · primary NCT02265705
  • 76.7% vs 61.9% wk 24 · n 159 · Phase 3 · primary NCT01711359
  • 78.1% vs 61.9% wk 24 · n 215 · Phase 3 · primary NCT01711359
  • 46.3% vs 27.3% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 44.8% vs 27.3% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 48.9% vs 27.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 73% vs 55.7% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 72.6% vs 55.7% wk 52 · n 215 · Phase 3 · secondary NCT01711359
52.7% vs 31.2%+21.5 vs placebo5 mg · wk 24 · n 311NCT00856544
273 other results
  • 51.5% vs 28.3% 5 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 51.5% vs 25.3% 5 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 59.8% vs 26.7% 5 mg · wk 12 · n 241 · Phase 3 · primary NCT00814307
  • 41.7% vs 24.4% 5 mg · wk 12 · n 132 · Phase 3 · primary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00856544
  • 52.5% vs 28.3% 10 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 61.8% vs 25.3% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 65.7% vs 26.7% 10 mg · wk 12 · n 242 · Phase 3 · primary NCT00814307
  • 48.1% vs 24.4% 10 mg · wk 12 · n 133 · Phase 3 · primary NCT00960440
  • 52.7% vs 31.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 50.8% vs 25.5% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 56.3% vs 27.4% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 60.7% vs 26.4% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 56.3% vs 27.3% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 56.9% vs 25.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 54.0% vs 26.1% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 46.5% vs 21.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 38.6% vs 22.9% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 41.2% vs 16.0% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 41.4% vs 16.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 42.4% vs 27.5% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 29.6% vs 11.8% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 10.9% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 27.7% vs 16.7% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 57.9% vs 25.5% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 64.7% vs 27.4% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 58.7% vs 26.4% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 66.3% vs 27.3% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 60.7% vs 25.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 64.4% vs 26.1% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 52.1% vs 21.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 48.5% vs 22.9% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 45.9% vs 16.0% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 52.1% vs 16.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 44.4% vs 27.5% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 39.2% vs 11.8% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 32.3% vs 10.9% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 32.8% vs 16.7% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 49.5% vs 49.3% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 67.8% vs 51.1% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 47.2% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 72.1% vs 55.4% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 68.8% vs 47.3% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 71.3% vs 50.5% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 46.7% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 69.9% vs 51.6% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 65.0% vs 45.1% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 63.6% vs 42.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 21.2% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 71.6% vs 51.1% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 47.2% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 73.6% vs 55.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 66.2% vs 47.3% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 76.1% vs 50.5% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 66.0% vs 46.7% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 77.9% vs 51.6% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 62.2% vs 45.1% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 71.6% vs 42.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 58.3% vs 21.2% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 73.1% vs 15.4% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT00687193
  • 61.2% vs 23.7% 5 mg · wk 12 · n 49 · Phase 2 · primary NCT00550446
  • 96.3% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 56.3% vs 36.2% 5 mg · wk 12 · n 71 · Phase 2 · primary NCT00413660
  • 70.5% vs 29.2% 5 mg BID · wk 6 · n 61 · Phase 2 · primary NCT00147498
  • 84.9% vs 15.4% 10 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 72.1% vs 23.7% 10 mg · wk 12 · n 61 · Phase 2 · primary NCT00550446
  • 80.8% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · primary NCT00603512
  • 58.1% vs 36.2% 10 mg · wk 12 · n 74 · Phase 2 · primary NCT00413660
  • 76.8% vs 29.2% 30 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 56.3% vs 36.2% 20 mg · wk 12 · n 80 · Phase 2 · primary NCT00413660
  • 90.7% vs 15.4% 15 mg · wk 12 · n 54 · Phase 2 · primary NCT00687193
  • 71.9% vs 23.7% 15 mg · wk 12 · n 57 · Phase 2 · primary NCT00550446
  • 56% vs 36.2% 15 mg · wk 12 · n 75 · Phase 2 · primary NCT00413660
  • 81.2% vs 29.2% 15 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 67.9% vs 15.4% 3 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 45.1% vs 23.7% 3 mg · wk 12 · n 51 · Phase 2 · primary NCT00550446
  • 77.8% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 55.9% vs 36.2% 3 mg · wk 12 · n 68 · Phase 2 · primary NCT00413660
  • 37.7% vs 15.4% 1 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 31.5% vs 23.7% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT00550446
  • 64.3% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · primary NCT00603512
  • 47.1% vs 36.2% 1 mg · wk 12 · n 70 · Phase 2 · primary NCT00413660
  • 57.1% vs 47.1% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 69.4% vs 32.4% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 57.7% vs 47.1% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 67.3% vs 35.3% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 53.5% vs 43.1% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 57.1% vs 23.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 67.3% vs 11.5% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 63.3% vs 27.1% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 96.3% vs 21.4% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.9% vs 33.3% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 50% vs 28.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 63.3% vs 25.4% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 57.8% vs 37.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 61.5% vs 9.6% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 40.8% vs 27.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 88.9% vs 10.7% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 46.5% vs 24.6% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 63.9% vs 30.8% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 34.6% vs 5.8% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 32.6% vs 15.3% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 63.0% vs 10.7% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 31.0% vs 15.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 50.8% vs 20% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 29.6% vs 3.6% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 27.9% vs 12.3% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 73.8% vs 47.1% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 66.2% vs 47.1% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 73.8% vs 32.4% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 62.2% vs 47.1% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 70.5% vs 35.3% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 64.9% vs 43.1% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 86.8% vs 11.5% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 65.6% vs 27.1% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 56.8% vs 33.3% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 55.4% vs 37.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 81.1% vs 9.6% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 46.0% vs 24.6% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 66% vs 5.8% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 70.6% vs 28.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 75.4% vs 30.8% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 68.1% vs 20% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 56.5% vs 12.3% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 62.7% vs 47.1% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 47.1% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 43.1% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 56.3% vs 33.3% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 50% vs 37.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 51.3% vs 24.6% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 33.8% vs 15.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 80.8% vs 21.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 63.9% vs 25.4% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 52.5% vs 27.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 76.9% vs 10.7% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 50.8% vs 15.3% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 31.1% vs 15.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 38.5% vs 3.6% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 68.4% vs 47.1% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 65.3% vs 47.1% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 32.4% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 61.3% vs 47.1% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 35.3% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 62.7% vs 43.1% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 87% vs 11.5% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 71.9% vs 27.1% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 64% vs 33.3% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 66.1% vs 28.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 66.7% vs 25.4% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 56% vs 37.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 77.8% vs 9.6% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 63.2% vs 27.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 54.7% vs 24.6% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 30.8% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 53.7% vs 5.8% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 38.6% vs 15.3% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 15.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 71.0% vs 20% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 43.5% vs 12.3% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 58.8% vs 47.1% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 65.5% vs 47.1% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 64.7% vs 32.4% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 67.3% vs 47.1% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 58.8% vs 35.3% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 60% vs 43.1% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 37.3% vs 23.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 62.3% vs 11.5% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 47.1% vs 27.1% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 66.7% vs 21.4% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.4% vs 33.3% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 47.1% vs 25.4% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 54.4% vs 37.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 47.2% vs 9.6% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 37.3% vs 27.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 55.6% vs 10.7% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 45.6% vs 24.6% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 34% vs 5.8% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 31.4% vs 15.3% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 40.7% vs 10.7% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 36.8% vs 15.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 14.8% vs 3.6% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 35.1% vs 47.1% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 45.9% vs 32.4% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 51.4% vs 35.3% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 63.3% vs 43.1% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 35.2% vs 23.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 37.7% vs 11.5% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 37.0% vs 27.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 67.9% vs 21.4% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 50% vs 33.3% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 38.9% vs 25.4% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 44.3% vs 37.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 35.8% vs 9.6% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 22.2% vs 27.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 37.1% vs 24.6% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 5.8% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 16.7% vs 15.3% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 82.6% vs 65.2% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 76% vs 76.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 32.1% vs 10.7% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 21.4% vs 15.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 28.6% vs 3.6% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 60% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 71% vs 66.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 70% vs 68% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.9% vs 66.8% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.7% vs 67.6% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.4% vs 64.6% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.3% vs 63.6% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.6% vs 65.4% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 57.2% vs 56% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.7% vs 63.5% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 66% vs 62.9% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.1% vs 64.2% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.3% vs 63.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.3% vs 61.1% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 61.6% vs 61.1% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.2% vs 60.9% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 53.6% vs 54.4% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 44% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.8% vs 35.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 29.8% vs 27.6% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 20.8% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 16.7% vs 16% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.8% vs 6.1% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.8% vs 2.5% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.7% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.1% vs 66.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 69% vs 68% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.9% vs 66.8% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 69.5% vs 67.6% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 66.9% vs 64.6% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 63.6% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 65.5% vs 65.4% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 59.5% vs 56% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 63.3% vs 63.5% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 63% vs 62.9% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 61.7% vs 64.2% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 61% vs 63.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 60.5% vs 61.1% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 57.9% vs 61.1% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 58.2% vs 60.9% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 49.3% vs 54.4% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.3% vs 44% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 33.3% vs 35.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.2% vs 27.6% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 20.8% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 16.3% vs 16% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.4% vs 11.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 6.9% vs 6.1% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.5% vs 2.5% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 0.7% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
ACR5044.1% vs 21.5%+22.6 vs placebo4 mg · wk 24 · n 227NCT01721057
13 other results
  • 29.4% vs 13.1% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 33.5% vs 12.7% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 28.2% vs 8% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 41.5% vs 21.5% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 23% vs 13.1% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 33.6% vs 12.7% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 20.1% vs 8% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 57.2% vs 37.6% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 61.9% vs 37.6% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 59.7% vs 43.3% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 63.3% vs 43.3% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 54.7% vs 32.9% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 60% vs 32.9% wk 12 · n 215 · Phase 3 · secondary NCT01711359
32.7% vs 16%+16.7 vs placebo5 mg · wk 52 · n 309NCT00847613
275 other results
  • 32.7% vs 20% 5 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 33.8% vs 12.7% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 36.7% vs 12.3% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 32.4% vs 8.4% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 28.0% vs 8.3% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 31.1% vs 12.5% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 9.6% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 34.2% vs 6.6% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 28.8% vs 7.8% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 26.5% vs 8.4% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 26.1% vs 5.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 23.1% vs 4.5% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 17.4% vs 4.2% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 11.6% vs 1.3% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 14.9% vs 4.7% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 16.8% vs 1.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 12.9% vs 6.1% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 5.8% vs 4.2% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 5.8% vs 1.3% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 7.7% vs 1.6% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 41.1% vs 16% 10 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 44.0% vs 20% 10 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 36.6% vs 12.7% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 34.7% vs 12.3% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 43.7% vs 8.4% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 33.3% vs 8.3% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 36.8% vs 12.5% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 34.0% vs 9.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 27.6% vs 6.6% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 36.3% vs 7.8% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 27.8% vs 8.4% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 33.9% vs 5.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 29.8% vs 4.5% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 24.0% vs 4.2% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 18.1% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 16.3% vs 4.7% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 18.4% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 17.3% vs 6.1% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 12.9% vs 4.2% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 8.1% vs 1.3% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 5.5% vs 1.6% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 36.7% vs 33.7% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 33.7% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 29.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 35.3% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 50.7% vs 33.1% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 46.6% vs 26.6% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 48.0% vs 30.4% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 40.1% vs 20.1% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 49.0% vs 30.4% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 32.6% vs 11.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 18.0% vs 3.8% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 28.3% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 33.7% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 55.6% vs 33.7% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 37.2% vs 29.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 56.9% vs 35.3% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 54.3% vs 33.1% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 56.4% vs 26.6% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 51.8% vs 30.4% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 50% vs 20.1% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 30.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 40.1% vs 11.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 28.0% vs 3.8% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 28.3% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 36.7% vs 17.6% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 39.4% vs 31.4% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 32.7% vs 17.6% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 31.4% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 20.6% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 21.6% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 46.2% vs 7.7% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 38.8% vs 10.2% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 81.5% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 36.6% vs 17.4% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 6.8% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 44.2% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 24.5% vs 8.5% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 70.4% vs 7.1% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 17.9% vs 13.3% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 14.3% vs 6.8% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 31.0% vs 8.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 28.8% vs 1.9% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 10.2% vs 5.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 29.6% vs 3.6% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 2.9% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 11.5% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 25.9% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.6% vs 2.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 3.1% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 6.6% vs 3.1% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 45.9% vs 17.6% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 39.2% vs 31.4% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 17.6% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 40.5% vs 31.4% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 20.6% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 36.5% vs 21.6% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 69.8% vs 7.7% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 45.9% vs 10.2% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 50.8% vs 6.8% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 62.3% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 29.5% vs 8.5% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 36.1% vs 6.8% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 54.7% vs 1.9% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 31.1% vs 5.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 32.1% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 18.0% vs 1.7% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 25% vs 2.9% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 15% vs 2.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 57.7% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 50% vs 7.1% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 27.0% vs 8.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 20.3% vs 2.9% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 26.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 4.0% vs 2.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 45.1% vs 13.3% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 50.7% vs 6.2% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 42.0% vs 6.2% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 29.0% vs 3.1% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 18.8% vs 3.1% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 31.4% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 47.8% vs 31.4% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 41.8% vs 21.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 36.3% vs 17.4% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 32.5% vs 17.4% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 27.5% vs 8.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 7.7% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 54.4% vs 17.6% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 46.7% vs 31.4% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 59.6% vs 17.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 48% vs 31.4% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 56.1% vs 20.6% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 21.6% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 72.2% vs 7.7% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 50.9% vs 10.2% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 44% vs 17.4% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 43.9% vs 6.8% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 66.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 49.1% vs 8.5% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 41.3% vs 17.4% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 30.4% vs 13.3% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 42.1% vs 6.8% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 8.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 53.6% vs 6.2% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 1.9% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 40.4% vs 5.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 26.7% vs 2.9% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 42.0% vs 6.2% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 22.2% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 17.5% vs 1.7% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 17.3% vs 2.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 23.2% vs 3.1% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 8.7% vs 3.1% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 44.1% vs 17.6% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 34.5% vs 31.4% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 44.1% vs 17.6% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 45.5% vs 31.4% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 38.2% vs 20.6% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 43.6% vs 21.6% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 26.4% vs 7.7% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 25.5% vs 10.2% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 44.4% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 29.4% vs 17.4% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 6.8% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 37.7% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 21.6% vs 8.5% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 29.6% vs 7.1% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 15.7% vs 6.8% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 29.4% vs 8.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 22.6% vs 1.9% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 13.7% vs 5.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 22.2% vs 3.6% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 16.2% vs 2.9% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 9.4% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 7.8% vs 1.7% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.9% vs 2.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 3.7% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 10.8% vs 17.6% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 44.9% vs 31.4% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 17.6% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 31.4% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 20.6% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 21.6% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 13.5% vs 7.7% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 11.1% vs 10.2% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 32.1% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 22.9% vs 17.4% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 13.0% vs 6.8% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 11.5% vs 1.9% 1 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 13.0% vs 8.5% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 7.1% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 17.1% vs 17.4% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 14.8% vs 6.8% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 10% vs 8.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 9.6% vs 1.9% 1 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 9.3% vs 5.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 10.7% vs 3.6% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 2.9% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 1.9% vs 1.7% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 2.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 67.4% vs 45.7% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 48% vs 42.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 7.1% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 40% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 43.4% vs 39.8% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 39.8% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.8% vs 40.1% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.6% vs 36.7% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.5% vs 42% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.3% vs 31.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.7% vs 41.9% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 27.6% vs 23.2% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.7% vs 40.8% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 41.1% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.2% vs 42% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.2% vs 40.9% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.4% vs 40.8% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.9% vs 38.7% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.7% vs 40.5% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 35.8% vs 35.8% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 29% vs 29.2% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.1% vs 23.8% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.5% vs 18.5% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 13.7% vs 14.4% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 6.9% vs 7.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 3.6% vs 3.8% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.1% vs 1.9% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.2% vs 0.5% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 39.8% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.7% vs 39.8% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 45.9% vs 40.1% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.2% vs 36.7% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.2% vs 42% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.5% vs 31.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.8% vs 41.9% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 31% vs 23.2% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.3% vs 40.8% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.3% vs 41.1% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.8% vs 42% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 42% vs 40.9% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.9% vs 40.8% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.4% vs 38.7% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 39.7% vs 40.5% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 33% vs 35.8% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.4% vs 29.2% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 23.8% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.6% vs 18.5% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 14.4% vs 14.4% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 7.1% vs 7.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 4.7% vs 3.8% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1.4% vs 1.9% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.4% vs 0.5% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
ACR7024.2% vs 7.9%+16.3 vs placebo4 mg · wk 24 · n 227NCT01721057
17 other results
  • 16.9% vs 3.4% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 18.1% vs 3.1% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 11.3% vs 2.3% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 25.3% vs 7.9% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 13.2% vs 3.4% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 17.9% vs 3.1% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 12.6% vs 2.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 42.1% vs 25.2% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 46% vs 25.2% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 42.1% vs 21.4% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 39.5% vs 21.4% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 30.8% vs 15.7% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 33.5% vs 15.7% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 29% vs 0% 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 29% vs 0% 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 21% vs 0% 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 13% vs 0% 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
25.4% vs 12.1%vs MTX5 mg BID · wk 24 · n 366NCT01039688
271 other results
  • 37.3% vs 12.1% 10 mg BID · wk 24 · n 391 · Phase 3 · primary NCT01039688
  • 13.2% vs 3.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 19.9% vs 1.9% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 14.6% vs 1.3% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 11.9% vs 3.2% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 15.3% vs 5.8% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 8.4% vs 1.9% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 12.2% vs 1.9% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 10.7% vs 2.6% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 13.6% vs 1.5% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 10.0% vs 3.3% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 9% vs 1.3% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 5.0% vs 1.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 3.5% vs 0% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 2.6% vs 0.9% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.9% vs 0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 7.6% vs 0% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 2.1% vs 0% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 0.3% vs 0% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 16.2% vs 3.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 21.9% vs 1.9% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 22.3% vs 1.3% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 18.1% vs 3.2% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 20.3% vs 5.8% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 14.2% vs 1.9% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 14.8% vs 1.9% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 17.1% vs 2.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 10.5% vs 1.5% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 19.0% vs 3.3% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 10.4% vs 1.3% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 9.1% vs 1.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 7.1% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 4.1% vs 0.9% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.6% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 6.8% vs 0% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 4.6% vs 0% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 2.3% vs 0% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 23.0% vs 16.6% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 28.7% vs 15.4% 5 mg BID · wk 52 · n 366 · Phase 3 · secondary NCT01039688
  • 18.4% vs 11.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 29.2% vs 13.2% 5 mg BID · wk 39 · n 366 · Phase 3 · secondary NCT01039688
  • 30.1% vs 17.0% 5 mg BID · wk 65 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 15.9% 5 mg BID · wk 78 · n 366 · Phase 3 · secondary NCT01039688
  • 19.9% vs 5.5% 5 mg BID · wk 13 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 17.6% 5 mg BID · wk 91 · n 366 · Phase 3 · secondary NCT01039688
  • 16.2% vs 3.3% 5 mg BID · wk 8.67 · n 366 · Phase 3 · secondary NCT01039688
  • 5.2% vs 0.6% 5 mg BID · wk 4.33 · n 366 · Phase 3 · secondary NCT01039688
  • 34.1% vs 15.4% 5 mg BID · wk 104 · n 366 · Phase 3 · secondary NCT01039688
  • 23.5% vs 16.6% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 15.4% 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • 21.9% vs 11.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 13.2% 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • 37.9% vs 17.0% 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • 36.6% vs 15.9% 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • 26.6% vs 5.5% 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • 36.8% vs 17.6% 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • 23.0% vs 3.3% 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • 9.2% vs 0.6% 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • 37.6% vs 15.4% 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • 22.4% vs 11.8% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 21.1% vs 9.8% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 18.4% vs 8.8% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 23.9% vs 13.7% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 20.4% vs 0% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 18.3% vs 9.8% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 26.9% vs 1.9% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 14.3% vs 3.4% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 18.3% vs 5.8% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 16.3% vs 1.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 25% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 5.8% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 8.9% vs 8.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 4.1% vs 1.7% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 16.9% vs 4.3% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 13.1% vs 3.1% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 17.3% vs 0% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 1.7% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 14.8% vs 0% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 0% vs 1.4% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 1.5% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 1.9% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 11.1% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 4.9% vs 1.5% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 1.6% vs 0% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 37.7% vs 11.8% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 31.1% vs 8.8% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 24.3% vs 13.7% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.5% vs 0% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 49.1% vs 1.9% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 24.6% vs 3.4% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 12.2% vs 5.8% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 37.7% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 16.2% vs 5.8% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 9.5% vs 4.3% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 26.4% vs 0% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 11.5% vs 1.7% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 9.4% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 3.3% vs 0% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 27.4% vs 8.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 27.5% vs 3.1% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 21.7% vs 1.5% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 10.1% vs 1.5% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 28.4% vs 9.8% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 28.4% vs 13.7% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 22.4% vs 9.8% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 23.8% vs 5.8% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 17.5% vs 5.8% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 4.3% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 1.4% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 2.5% vs 0% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 26.2% vs 1.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 18.0% vs 1.7% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 26.9% vs 3.6% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 19.7% vs 1.7% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 7.7% vs 0% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 14.9% vs 1.4% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 33.3% vs 11.8% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 9.8% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 31.6% vs 8.8% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 28% vs 13.7% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 33.3% vs 0% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 9.8% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 51.9% vs 1.9% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 26.3% vs 3.4% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 5.8% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 21.1% vs 1.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 40.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 24.6% vs 1.7% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 5.8% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 14.3% vs 8.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 17.5% vs 1.7% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 4.3% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 21.7% vs 3.1% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 16.7% vs 0% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 8.8% vs 1.7% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 13.3% vs 1.4% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 17.4% vs 1.5% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 7.4% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 6.7% vs 0% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 4.3% vs 1.5% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 23.5% vs 11.8% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 23.6% vs 9.8% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 8.8% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 29.1% vs 13.7% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 26.5% vs 0% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 21.8% vs 9.8% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 13.2% vs 1.9% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 11.8% vs 3.4% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.6% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 20.6% vs 5.8% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 7.8% vs 1.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 3.9% vs 1.7% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 3.6% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 14.7% vs 5.8% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 2.0% vs 1.7% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 4.3% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 3.8% vs 0% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 5.9% vs 1.7% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 7.3% vs 1.4% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 3.7% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.5% vs 0% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 8.1% vs 11.8% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 9.8% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 8.8% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 20.4% vs 13.7% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 0% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 16.3% vs 9.8% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 7.5% vs 1.9% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 5.6% vs 3.4% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 3.6% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 5.8% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 5.7% vs 1.9% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 9.3% vs 1.7% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 3.6% vs 3.6% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 8.6% vs 5.8% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 1.4% vs 4.3% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 0% vs 1.7% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 0% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 1.9% vs 0% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 34.8% vs 30.4% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 20% vs 19.1% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 3.6% vs 0% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 2.9% vs 1.4% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 6.7% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 23.2% vs 19.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.5% vs 20.1% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.7% vs 21% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.4% vs 16.1% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.6% vs 22.4% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.4% vs 13.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 22.2% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 7.8% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 24% vs 22.6% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.7% vs 23.6% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.4% vs 24.7% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.5% vs 24.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 24.2% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.5% vs 23.3% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.8% vs 23.6% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 21.5% vs 20.5% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.6% vs 16.4% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 14.8% vs 13.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.9% vs 11% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 8.8% vs 8.1% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.4% vs 6.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 4% vs 4.4% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.7% vs 2.4% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.5% vs 1% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.1% vs 0.3% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.6% vs 19.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.2% vs 20.1% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 21% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 22.7% vs 16.1% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.2% vs 22.4% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.4% vs 13.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.4% vs 22.2% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.3% vs 7.8% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.5% vs 22.6% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 23.6% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.3% vs 24.7% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.9% vs 24.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.6% vs 24.2% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 24.8% vs 23.3% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.5% vs 23.6% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 20.5% vs 20.5% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 15.7% vs 16.4% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.4% vs 13.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 8.7% vs 8.1% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 5.7% vs 6.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 3.9% vs 4.4% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.6% vs 2.4% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 1% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.3% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
DAS28-CRP remission—Trial running · NCT0487020323.0% vs 5.2%+17.8 vs placebo5 mg · wk 26 · n 309NCT00847613
174 other results
  • 20.4% vs 5.2% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 11.3% vs 2.0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 36.4% vs 5.2% 10 mg · wk 26 · n 308 · Phase 3 · secondary NCT00847613
  • 26.9% vs 5.2% 10 mg · wk 13 · n 308 · Phase 3 · secondary NCT00847613
  • 9.1% vs 2.0% 10 mg · wk 4.33 · n 308 · Phase 3 · secondary NCT00847613
  • 38.4% vs 18.5% 5 mg BID · wk 104 · n 367 · Phase 3 · secondary NCT01039688
  • 37.1% vs 17.4% 5 mg BID · wk 91 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 19.0% 5 mg BID · wk 78 · n 367 · Phase 3 · secondary NCT01039688
  • 37.6% vs 19.6% 5 mg BID · wk 65 · n 367 · Phase 3 · secondary NCT01039688
  • 36.5% vs 20.6% 5 mg BID · wk 52 · n 367 · Phase 3 · secondary NCT01039688
  • 36.2% vs 17.4% 5 mg BID · wk 39 · n 367 · Phase 3 · secondary NCT01039688
  • 31.3% vs 15.2% 5 mg BID · wk 26 · n 367 · Phase 3 · secondary NCT01039688
  • 25.9% vs 9.8% 5 mg BID · wk 13 · n 367 · Phase 3 · secondary NCT01039688
  • 20.4% vs 5.4% 5 mg BID · wk 8.67 · n 367 · Phase 3 · secondary NCT01039688
  • 7.4% vs 2.7% 5 mg BID · wk 4.33 · n 367 · Phase 3 · secondary NCT01039688
  • 43.9% vs 18.5% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 17.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 19.0% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 19.6% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 49.5% vs 20.6% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 45.7% vs 17.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 47.2% vs 15.2% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 37.8% vs 9.8% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 28.7% vs 5.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 14.1% vs 2.7% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 65.9% vs 30% 5 mg · wk 24 · n 40 · Phase 2 · secondary NCT00550446
  • 22% vs 15% 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • 41.5% vs 19.4% 5 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 68.9% vs 16.7% 5 mg · wk 20 · n 40 · Phase 2 · secondary NCT00550446
  • 20% vs 5.6% 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • 35.1% vs 13.9% 5 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 69.6% vs 35% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT00550446
  • 28.3% vs 15% 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • 24.1% vs 8.1% 5 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 6.7% 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT00550446
  • 24.4% vs 6.7% 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • 16.7% vs 6.7% 5 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 65.8% vs 3.3% 5 mg · wk 10 · n 40 · Phase 2 · secondary NCT00550446
  • 21.7% vs 4.3% 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • 66.7% vs 9.7% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT00550446
  • 14.9% vs 4.4% 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • 19.4% vs 6.9% 5 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 56.4% vs 5.9% 5 mg · wk 6 · n 40 · Phase 2 · secondary NCT00550446
  • 8.9% vs 1.9% 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • 13.6% vs 3.5% 5 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT00550446
  • 4.4% vs 1.9% 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • 8.1% vs 3.3% 5 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 62.5% vs 2.7% 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT00550446
  • 4.2% vs 0% 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 5 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 72.7% vs 30% 10 mg · wk 24 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT00550446
  • 36.5% vs 19.4% 10 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 88.7% vs 16.7% 10 mg · wk 20 · n 45 · Phase 2 · secondary NCT00550446
  • 43.4% vs 5.6% 10 mg · wk 20 · n 60 · Phase 2 · secondary NCT00550446
  • 37.1% vs 13.9% 10 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 78.2% vs 35% 10 mg · wk 16 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 16 · n 60 · Phase 2 · secondary NCT00550446
  • 30.2% vs 8.1% 10 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 75.6% vs 6.7% 10 mg · wk 12 · n 45 · Phase 2 · secondary NCT00550446
  • 33.3% vs 6.7% 10 mg · wk 12 · n 60 · Phase 2 · secondary NCT00550446
  • 32.3% vs 6.7% 10 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 90.7% vs 3.3% 10 mg · wk 10 · n 45 · Phase 2 · secondary NCT00550446
  • 31.6% vs 4.3% 10 mg · wk 10 · n 60 · Phase 2 · secondary NCT00550446
  • 78.6% vs 9.7% 10 mg · wk 8 · n 45 · Phase 2 · secondary NCT00550446
  • 21.4% vs 4.4% 10 mg · wk 8 · n 60 · Phase 2 · secondary NCT00550446
  • 21.3% vs 6.9% 10 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 79.5% vs 5.9% 10 mg · wk 6 · n 45 · Phase 2 · secondary NCT00550446
  • 24.1% vs 1.9% 10 mg · wk 6 · n 60 · Phase 2 · secondary NCT00550446
  • 24.2% vs 3.5% 10 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 83.7% vs 5.7% 10 mg · wk 4 · n 45 · Phase 2 · secondary NCT00550446
  • 17.5% vs 1.9% 10 mg · wk 4 · n 60 · Phase 2 · secondary NCT00550446
  • 19.1% vs 3.3% 10 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 71.1% vs 2.7% 10 mg · wk 2 · n 45 · Phase 2 · secondary NCT00550446
  • 5% vs 0% 10 mg · wk 2 · n 60 · Phase 2 · secondary NCT00550446
  • 4.4% vs 3.3% 10 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 32.7% vs 19.4% 20 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 30.9% vs 13.9% 20 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.1% vs 8.1% 20 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 24.6% vs 6.7% 20 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 20.9% vs 6.9% 20 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 10.1% vs 3.5% 20 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 10% vs 3.3% 20 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 4.0% vs 3.3% 20 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 84.6% vs 30% 15 mg · wk 24 · n 39 · Phase 2 · secondary NCT00550446
  • 50% vs 15% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 39.3% vs 19.4% 15 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 76.9% vs 16.7% 15 mg · wk 20 · n 39 · Phase 2 · secondary NCT00550446
  • 42.3% vs 5.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 38.6% vs 13.9% 15 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 82.4% vs 35% 15 mg · wk 16 · n 39 · Phase 2 · secondary NCT00550446
  • 43.1% vs 15% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 37.9% vs 8.1% 15 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 68.6% vs 6.7% 15 mg · wk 12 · n 39 · Phase 2 · secondary NCT00550446
  • 40.4% vs 6.7% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 37.1% vs 6.7% 15 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 79.4% vs 3.3% 15 mg · wk 10 · n 39 · Phase 2 · secondary NCT00550446
  • 38.5% vs 4.3% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 75% vs 9.7% 15 mg · wk 8 · n 39 · Phase 2 · secondary NCT00550446
  • 41.5% vs 4.4% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 23.9% vs 6.9% 15 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 67.6% vs 5.9% 15 mg · wk 6 · n 39 · Phase 2 · secondary NCT00550446
  • 32.7% vs 1.9% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 22.7% vs 3.5% 15 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 15 mg · wk 4 · n 39 · Phase 2 · secondary NCT00550446
  • 15.1% vs 1.9% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 16.9% vs 3.3% 15 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 66.7% vs 2.7% 15 mg · wk 2 · n 39 · Phase 2 · secondary NCT00550446
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 13.2% vs 3.3% 15 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 46.4% vs 30% 3 mg · wk 24 · n 33 · Phase 2 · secondary NCT00550446
  • 39.3% vs 15% 3 mg · wk 24 · n 50 · Phase 2 · secondary NCT00550446
  • 35.7% vs 19.4% 3 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 58.6% vs 16.7% 3 mg · wk 20 · n 33 · Phase 2 · secondary NCT00550446
  • 20.7% vs 5.6% 3 mg · wk 20 · n 50 · Phase 2 · secondary NCT00550446
  • 43.2% vs 13.9% 3 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 35% 3 mg · wk 16 · n 33 · Phase 2 · secondary NCT00550446
  • 30% vs 15% 3 mg · wk 16 · n 50 · Phase 2 · secondary NCT00550446
  • 41.9% vs 8.1% 3 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 42.9% vs 6.7% 3 mg · wk 12 · n 33 · Phase 2 · secondary NCT00550446
  • 8.9% vs 6.7% 3 mg · wk 12 · n 50 · Phase 2 · secondary NCT00550446
  • 30.9% vs 6.7% 3 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 3.3% 3 mg · wk 10 · n 33 · Phase 2 · secondary NCT00550446
  • 8.5% vs 4.3% 3 mg · wk 10 · n 50 · Phase 2 · secondary NCT00550446
  • 46.7% vs 9.7% 3 mg · wk 8 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 4.4% 3 mg · wk 8 · n 50 · Phase 2 · secondary NCT00550446
  • 22.0% vs 6.9% 3 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 43.3% vs 5.9% 3 mg · wk 6 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 1.9% 3 mg · wk 6 · n 50 · Phase 2 · secondary NCT00550446
  • 19.7% vs 3.5% 3 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 5.7% 3 mg · wk 4 · n 33 · Phase 2 · secondary NCT00550446
  • 6.5% vs 1.9% 3 mg · wk 4 · n 50 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.3% 3 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 2.7% 3 mg · wk 2 · n 33 · Phase 2 · secondary NCT00550446
  • 4% vs 0% 3 mg · wk 2 · n 50 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.3% 3 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 30% 1 mg · wk 24 · n 43 · Phase 2 · secondary NCT00550446
  • 16.7% vs 15% 1 mg · wk 24 · n 53 · Phase 2 · secondary NCT00550446
  • 23.1% vs 19.4% 1 mg · wk 24 · n 64 · Phase 2 · secondary NCT00413660
  • 46.2% vs 16.7% 1 mg · wk 20 · n 43 · Phase 2 · secondary NCT00550446
  • 19.2% vs 5.6% 1 mg · wk 20 · n 53 · Phase 2 · secondary NCT00550446
  • 20.5% vs 13.9% 1 mg · wk 20 · n 64 · Phase 2 · secondary NCT00413660
  • 48.1% vs 35% 1 mg · wk 16 · n 43 · Phase 2 · secondary NCT00550446
  • 22.2% vs 15% 1 mg · wk 16 · n 53 · Phase 2 · secondary NCT00550446
  • 14.3% vs 8.1% 1 mg · wk 16 · n 64 · Phase 2 · secondary NCT00413660
  • 22.2% vs 6.7% 1 mg · wk 12 · n 43 · Phase 2 · secondary NCT00550446
  • 9.3% vs 6.7% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00550446
  • 6.6% vs 6.7% 1 mg · wk 12 · n 64 · Phase 2 · secondary NCT00413660
  • 26.3% vs 3.3% 1 mg · wk 10 · n 43 · Phase 2 · secondary NCT00550446
  • 10.9% vs 4.3% 1 mg · wk 10 · n 53 · Phase 2 · secondary NCT00550446
  • 25.6% vs 9.7% 1 mg · wk 8 · n 43 · Phase 2 · secondary NCT00550446
  • 2.1% vs 4.4% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00550446
  • 7.9% vs 6.9% 1 mg · wk 8 · n 64 · Phase 2 · secondary NCT00413660
  • 20.5% vs 5.9% 1 mg · wk 6 · n 43 · Phase 2 · secondary NCT00550446
  • 8.5% vs 1.9% 1 mg · wk 6 · n 53 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.5% 1 mg · wk 6 · n 64 · Phase 2 · secondary NCT00413660
  • 30% vs 5.7% 1 mg · wk 4 · n 43 · Phase 2 · secondary NCT00550446
  • 6% vs 1.9% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00550446
  • 4.6% vs 3.3% 1 mg · wk 4 · n 64 · Phase 2 · secondary NCT00413660
  • 25.6% vs 2.7% 1 mg · wk 2 · n 43 · Phase 2 · secondary NCT00550446
  • 1.9% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 1 mg · wk 2 · n 64 · Phase 2 · secondary NCT00413660
  • 16.7% vs 19.4% 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • 0% vs 13.9% 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • 11.1% vs 8.1% 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • 15.4% vs 19.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 15.4% vs 13.9% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 23.1% vs 8.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 25% vs 19.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 28.6% vs 13.9% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 9.5% vs 8.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 24% vs 22.4% 11mg MR · wk 24 · n 100 · Phase 2 · secondary NCT04413617
  • 40.8% vs 22.4% 400mg MR + 11mg MR · wk 24 · n 103 · Phase 2 · secondary NCT04413617
HAQ-DI, change-0.5 vs -0.3−0.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • -0.4 vs -0.2 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • -0.5 vs -0.3 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • -0.4 vs -0.2 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • -0.7 vs -0.3 wk 12 · n 487 · Phase 3 · secondary NCT01710358
  • -0.6 vs -0.3 wk 12 · n 144 · Phase 3 · secondary NCT02265705
  • -1.0 vs -0.7 wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • -0.9 vs -0.7 wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • -0.5 vs -0.1 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.3 vs -0.1 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
-0.5 vs -0.2−0.3 vs placebo5 mg · wk 13 · n 240NCT00814307
233 other results
  • -0.5 vs -0.2 5 mg · wk 13 · n 311 · Phase 3 · primary NCT00856544
  • -0.5 vs -0.2 5 mg twice daily · wk 13 · n 201 · Phase 3 · primary NCT00853385
  • -0.3 vs -0.1 5 mg · wk 13 · n 315 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 5 mg · wk 13 · n 132 · Phase 3 · primary NCT00960440
  • -0.5 vs -0.2 10 mg · wk 13 · n 241 · Phase 3 · primary NCT00814307
  • -0.5 vs -0.2 10 mg · wk 13 · n 315 · Phase 3 · primary NCT00856544
  • -0.6 vs -0.2 10 mg twice daily · wk 13 · n 199 · Phase 3 · primary NCT00853385
  • -0.4 vs -0.1 10 mg · wk 13 · n 309 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 10 mg · wk 13 · n 134 · Phase 3 · primary NCT00960440
  • -0.8 vs -0.6 5 mg BID · wk 26 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 5 mg BID · wk 13 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.7 5 mg BID · wk 39 · n 365 · Phase 3 · secondary NCT01039688
  • -0.7 vs -0.3 5 mg BID · wk 8.67 · n 365 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.2 5 mg BID · wk 4.33 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 52 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 65 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 78 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 91 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 104 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.6 10 mg BID · wk 26 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.3 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • -0.6 vs -0.2 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • -1 vs -0.7 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.4 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.3 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 5 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs 0.2 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 5 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.2 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.2 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.0 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 5 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 5 mg BID · wk 8 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.2 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 5 mg BID · wk 6 · n 59 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.0 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 5 mg BID · wk 4 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs 0.1 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • -0.2 vs -0.0 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.0 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 5 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 5 mg BID · wk 2 · n 59 · Phase 2 · secondary NCT00147498
  • -0.1 vs 0 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg BID · wk 1 · n 59 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.4 10 mg · wk 24 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 20 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 16 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.3 10 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.2 10 mg · wk 12 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.2 10 mg · wk 10 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.5 vs -0.2 10 mg · wk 8 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.2 10 mg · wk 6 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 10 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.1 10 mg · wk 4 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.1 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 10 mg · wk 2 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 20 mg · wk 4 · n 79 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.1 20 mg · wk 2 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 10 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.0 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 10 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 30 mg BID · wk 8 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 30 mg BID · wk 6 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.1 30 mg BID · wk 4 · n 64 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.1 30 mg BID · wk 2 · n 64 · Phase 2 · secondary NCT00147498
  • -0.4 vs -0.1 30 mg BID · wk 1 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.4 20 mg · wk 24 · n 79 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.4 20 mg · wk 20 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 20 mg · wk 16 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 20 mg · wk 8 · n 79 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 20 mg · wk 6 · n 79 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • -0.8 vs -0.4 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 15 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • -0.8 vs -0.2 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 15 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.8 vs -0.2 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • -0.7 vs -0.2 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 15 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 15 mg BID · wk 8 · n 68 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 15 mg BID · wk 6 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs 0.0 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.1 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 15 mg BID · wk 4 · n 68 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.1 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.0 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 15 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 15 mg BID · wk 2 · n 68 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.1 15 mg BID · wk 1 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs -0.4 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 3 mg · wk 24 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 3 mg · wk 20 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.3 3 mg · wk 16 · n 66 · Phase 2 · secondary NCT00413660
  • -0.4 vs 0.2 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 3 mg · wk 12 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.2 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs 0.0 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 8 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 6 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0.0 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 4 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.0 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 3 mg · wk 2 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.6 vs -0.4 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 1 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.2 vs 0.2 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 1 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs 0.2 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.0 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 1 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 1 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.0 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.1 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 1 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.0 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • -0.1 vs -0.0 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • -0.1 vs -0.1 1 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • 0.1 vs -0.1 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • -0.4 vs -0.0 wk 6 · n 93 · Phase 1 · secondary NCT01484561
  • -0.5 vs -0.4 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.4 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.4 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.3 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.3 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.5 5 mg BID · wk 26 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 5 mg BID · wk 13 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 39 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.4 vs -0.4 5 mg BID · wk 8.67 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 52 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 65 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 78 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 91 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 104 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 117 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 130 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 143 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 156 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 169 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 182 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 195 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 208 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 221 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 234 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 247 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 260 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 273 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 26 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 13 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 39 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 8.67 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 52 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 65 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 78 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 91 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 104 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 117 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 130 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 143 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 156 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 169 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 182 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 195 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 208 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 221 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 234 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 247 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 260 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 273 · n 1390 · Phase 4 · secondary NCT02092467
Modified Sharp score, change0.3 vs 0.8−0.5 vs placebowk 24 · n 470NCT01710358
2 other results
  • 0.4 vs 0.6 wk 24 · n 152 · Phase 3 · secondary NCT01711359
  • 0.3 vs 0.6 wk 24 · n 198 · Phase 3 · secondary NCT01711359
0.1 vs 0.5−0.3 vs placebo5 mg · wk 26 · n 286NCT00847613
7 other results
  • 0.1 vs 0.5 10 mg · wk 26 · n 295 · Phase 3 · primary NCT00847613
  • 0.2 vs 0.7 5 mg BID · wk 24 · n 346 · Phase 3 · primary NCT01039688
  • 0.1 vs 0.7 10 mg BID · wk 24 · n 370 · Phase 3 · primary NCT01039688
  • 0.4 vs 1.2 5 mg BID · wk 52 · n 346 · Phase 3 · secondary NCT01039688
  • 0.6 vs 2.1 5 mg BID · wk 104 · n 346 · Phase 3 · secondary NCT01039688
  • 0.2 vs 1.2 10 mg BID · wk 52 · n 371 · Phase 3 · secondary NCT01039688
  • 0.3 vs 2.1 10 mg BID · wk 104 · n 371 · Phase 3 · secondary NCT01039688

ACR20

baricitinib
61.7% vs 39.5%+22.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • 55.4% vs 27.3% 4 mg · wk 12 · n 177 · Phase 3 · primary NCT01721044
  • 65.9% vs 39.5% 2 mg · wk 12 · n 229 · Phase 3 · primary NCT01721057
  • 69.6% vs 40.2% wk 12 · n 487 · Phase 3 · primary NCT01710358
  • 58.6% vs 28.3% wk 12 · n 145 · Phase 3 · primary NCT02265705
  • 76.7% vs 61.9% wk 24 · n 159 · Phase 3 · primary NCT01711359
  • 78.1% vs 61.9% wk 24 · n 215 · Phase 3 · primary NCT01711359
  • 46.3% vs 27.3% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 44.8% vs 27.3% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 48.9% vs 27.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 73% vs 55.7% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 72.6% vs 55.7% wk 52 · n 215 · Phase 3 · secondary NCT01711359
tofacitinib
52.7% vs 31.2%+21.5 vs placebo5 mg · wk 24 · n 311NCT00856544
273 other results
  • 51.5% vs 28.3% 5 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 51.5% vs 25.3% 5 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 59.8% vs 26.7% 5 mg · wk 12 · n 241 · Phase 3 · primary NCT00814307
  • 41.7% vs 24.4% 5 mg · wk 12 · n 132 · Phase 3 · primary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00856544
  • 52.5% vs 28.3% 10 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 61.8% vs 25.3% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 65.7% vs 26.7% 10 mg · wk 12 · n 242 · Phase 3 · primary NCT00814307
  • 48.1% vs 24.4% 10 mg · wk 12 · n 133 · Phase 3 · primary NCT00960440
  • 52.7% vs 31.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 50.8% vs 25.5% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 56.3% vs 27.4% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 60.7% vs 26.4% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 56.3% vs 27.3% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 56.9% vs 25.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 54.0% vs 26.1% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 46.5% vs 21.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 38.6% vs 22.9% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 41.2% vs 16.0% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 41.4% vs 16.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 42.4% vs 27.5% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 29.6% vs 11.8% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 10.9% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 27.7% vs 16.7% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 57.9% vs 25.5% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 64.7% vs 27.4% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 58.7% vs 26.4% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 66.3% vs 27.3% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 60.7% vs 25.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 64.4% vs 26.1% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 52.1% vs 21.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 48.5% vs 22.9% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 45.9% vs 16.0% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 52.1% vs 16.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 44.4% vs 27.5% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 39.2% vs 11.8% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 32.3% vs 10.9% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 32.8% vs 16.7% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 49.5% vs 49.3% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 67.8% vs 51.1% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 47.2% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 72.1% vs 55.4% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 68.8% vs 47.3% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 71.3% vs 50.5% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 46.7% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 69.9% vs 51.6% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 65.0% vs 45.1% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 63.6% vs 42.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 21.2% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 71.6% vs 51.1% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 47.2% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 73.6% vs 55.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 66.2% vs 47.3% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 76.1% vs 50.5% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 66.0% vs 46.7% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 77.9% vs 51.6% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 62.2% vs 45.1% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 71.6% vs 42.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 58.3% vs 21.2% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 73.1% vs 15.4% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT00687193
  • 61.2% vs 23.7% 5 mg · wk 12 · n 49 · Phase 2 · primary NCT00550446
  • 96.3% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 56.3% vs 36.2% 5 mg · wk 12 · n 71 · Phase 2 · primary NCT00413660
  • 70.5% vs 29.2% 5 mg BID · wk 6 · n 61 · Phase 2 · primary NCT00147498
  • 84.9% vs 15.4% 10 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 72.1% vs 23.7% 10 mg · wk 12 · n 61 · Phase 2 · primary NCT00550446
  • 80.8% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · primary NCT00603512
  • 58.1% vs 36.2% 10 mg · wk 12 · n 74 · Phase 2 · primary NCT00413660
  • 76.8% vs 29.2% 30 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 56.3% vs 36.2% 20 mg · wk 12 · n 80 · Phase 2 · primary NCT00413660
  • 90.7% vs 15.4% 15 mg · wk 12 · n 54 · Phase 2 · primary NCT00687193
  • 71.9% vs 23.7% 15 mg · wk 12 · n 57 · Phase 2 · primary NCT00550446
  • 56% vs 36.2% 15 mg · wk 12 · n 75 · Phase 2 · primary NCT00413660
  • 81.2% vs 29.2% 15 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 67.9% vs 15.4% 3 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 45.1% vs 23.7% 3 mg · wk 12 · n 51 · Phase 2 · primary NCT00550446
  • 77.8% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 55.9% vs 36.2% 3 mg · wk 12 · n 68 · Phase 2 · primary NCT00413660
  • 37.7% vs 15.4% 1 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 31.5% vs 23.7% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT00550446
  • 64.3% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · primary NCT00603512
  • 47.1% vs 36.2% 1 mg · wk 12 · n 70 · Phase 2 · primary NCT00413660
  • 57.1% vs 47.1% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 69.4% vs 32.4% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 57.7% vs 47.1% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 67.3% vs 35.3% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 53.5% vs 43.1% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 57.1% vs 23.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 67.3% vs 11.5% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 63.3% vs 27.1% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 96.3% vs 21.4% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.9% vs 33.3% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 50% vs 28.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 63.3% vs 25.4% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 57.8% vs 37.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 61.5% vs 9.6% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 40.8% vs 27.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 88.9% vs 10.7% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 46.5% vs 24.6% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 63.9% vs 30.8% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 34.6% vs 5.8% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 32.6% vs 15.3% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 63.0% vs 10.7% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 31.0% vs 15.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 50.8% vs 20% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 29.6% vs 3.6% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 27.9% vs 12.3% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 73.8% vs 47.1% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 66.2% vs 47.1% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 73.8% vs 32.4% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 62.2% vs 47.1% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 70.5% vs 35.3% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 64.9% vs 43.1% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 86.8% vs 11.5% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 65.6% vs 27.1% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 56.8% vs 33.3% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 55.4% vs 37.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 81.1% vs 9.6% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 46.0% vs 24.6% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 66% vs 5.8% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 70.6% vs 28.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 75.4% vs 30.8% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 68.1% vs 20% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 56.5% vs 12.3% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 62.7% vs 47.1% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 47.1% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 43.1% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 56.3% vs 33.3% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 50% vs 37.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 51.3% vs 24.6% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 33.8% vs 15.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 80.8% vs 21.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 63.9% vs 25.4% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 52.5% vs 27.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 76.9% vs 10.7% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 50.8% vs 15.3% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 31.1% vs 15.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 38.5% vs 3.6% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 68.4% vs 47.1% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 65.3% vs 47.1% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 32.4% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 61.3% vs 47.1% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 35.3% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 62.7% vs 43.1% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 87% vs 11.5% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 71.9% vs 27.1% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 64% vs 33.3% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 66.1% vs 28.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 66.7% vs 25.4% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 56% vs 37.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 77.8% vs 9.6% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 63.2% vs 27.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 54.7% vs 24.6% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 30.8% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 53.7% vs 5.8% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 38.6% vs 15.3% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 15.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 71.0% vs 20% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 43.5% vs 12.3% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 58.8% vs 47.1% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 65.5% vs 47.1% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 64.7% vs 32.4% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 67.3% vs 47.1% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 58.8% vs 35.3% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 60% vs 43.1% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 37.3% vs 23.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 62.3% vs 11.5% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 47.1% vs 27.1% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 66.7% vs 21.4% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.4% vs 33.3% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 47.1% vs 25.4% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 54.4% vs 37.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 47.2% vs 9.6% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 37.3% vs 27.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 55.6% vs 10.7% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 45.6% vs 24.6% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 34% vs 5.8% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 31.4% vs 15.3% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 40.7% vs 10.7% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 36.8% vs 15.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 14.8% vs 3.6% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 35.1% vs 47.1% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 45.9% vs 32.4% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 51.4% vs 35.3% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 63.3% vs 43.1% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 35.2% vs 23.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 37.7% vs 11.5% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 37.0% vs 27.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 67.9% vs 21.4% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 50% vs 33.3% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 38.9% vs 25.4% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 44.3% vs 37.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 35.8% vs 9.6% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 22.2% vs 27.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 37.1% vs 24.6% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 5.8% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 16.7% vs 15.3% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 82.6% vs 65.2% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 76% vs 76.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 32.1% vs 10.7% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 21.4% vs 15.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 28.6% vs 3.6% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 60% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 71% vs 66.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 70% vs 68% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.9% vs 66.8% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.7% vs 67.6% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.4% vs 64.6% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.3% vs 63.6% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.6% vs 65.4% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 57.2% vs 56% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.7% vs 63.5% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 66% vs 62.9% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.1% vs 64.2% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.3% vs 63.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.3% vs 61.1% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 61.6% vs 61.1% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.2% vs 60.9% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 53.6% vs 54.4% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 44% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.8% vs 35.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 29.8% vs 27.6% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 20.8% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 16.7% vs 16% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.8% vs 6.1% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.8% vs 2.5% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.7% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 68.1% vs 66.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 69% vs 68% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.9% vs 66.8% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 69.5% vs 67.6% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 66.9% vs 64.6% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 63.6% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 65.5% vs 65.4% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 59.5% vs 56% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 63.3% vs 63.5% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 63% vs 62.9% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 61.7% vs 64.2% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 61% vs 63.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 60.5% vs 61.1% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 57.9% vs 61.1% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 58.2% vs 60.9% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 49.3% vs 54.4% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.3% vs 44% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 33.3% vs 35.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.2% vs 27.6% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 20.8% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 16.3% vs 16% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.4% vs 11.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 6.9% vs 6.1% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.5% vs 2.5% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 0.7% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467

ACR50

baricitinib
44.1% vs 21.5%+22.6 vs placebo4 mg · wk 24 · n 227NCT01721057
13 other results
  • 29.4% vs 13.1% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 33.5% vs 12.7% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 28.2% vs 8% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 41.5% vs 21.5% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 23% vs 13.1% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 33.6% vs 12.7% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 20.1% vs 8% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 57.2% vs 37.6% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 61.9% vs 37.6% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 59.7% vs 43.3% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 63.3% vs 43.3% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 54.7% vs 32.9% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 60% vs 32.9% wk 12 · n 215 · Phase 3 · secondary NCT01711359
tofacitinib
32.7% vs 16%+16.7 vs placebo5 mg · wk 52 · n 309NCT00847613
275 other results
  • 32.7% vs 20% 5 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 33.8% vs 12.7% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 36.7% vs 12.3% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 32.4% vs 8.4% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 28.0% vs 8.3% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 31.1% vs 12.5% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 9.6% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 34.2% vs 6.6% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 28.8% vs 7.8% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 26.5% vs 8.4% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 26.1% vs 5.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 23.1% vs 4.5% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 17.4% vs 4.2% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 11.6% vs 1.3% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 14.9% vs 4.7% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 16.8% vs 1.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 12.9% vs 6.1% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 5.8% vs 4.2% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 5.8% vs 1.3% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 7.7% vs 1.6% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 41.1% vs 16% 10 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 44.0% vs 20% 10 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 36.6% vs 12.7% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 34.7% vs 12.3% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 43.7% vs 8.4% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 33.3% vs 8.3% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 36.8% vs 12.5% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 34.0% vs 9.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 27.6% vs 6.6% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 36.3% vs 7.8% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 27.8% vs 8.4% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 33.9% vs 5.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 29.8% vs 4.5% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 24.0% vs 4.2% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 18.1% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 16.3% vs 4.7% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 18.4% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 17.3% vs 6.1% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 12.9% vs 4.2% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 8.1% vs 1.3% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 5.5% vs 1.6% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 36.7% vs 33.7% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 33.7% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 29.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 35.3% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 50.7% vs 33.1% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 46.6% vs 26.6% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 48.0% vs 30.4% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 40.1% vs 20.1% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 49.0% vs 30.4% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 32.6% vs 11.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 18.0% vs 3.8% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 28.3% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 33.7% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 55.6% vs 33.7% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 37.2% vs 29.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 56.9% vs 35.3% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 54.3% vs 33.1% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 56.4% vs 26.6% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 51.8% vs 30.4% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 50% vs 20.1% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 30.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 40.1% vs 11.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 28.0% vs 3.8% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 28.3% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 36.7% vs 17.6% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 39.4% vs 31.4% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 32.7% vs 17.6% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 31.4% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 20.6% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 21.6% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 46.2% vs 7.7% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 38.8% vs 10.2% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 81.5% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 36.6% vs 17.4% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 6.8% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 44.2% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 24.5% vs 8.5% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 70.4% vs 7.1% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 17.9% vs 13.3% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 14.3% vs 6.8% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 31.0% vs 8.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 28.8% vs 1.9% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 10.2% vs 5.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 29.6% vs 3.6% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 2.9% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 11.5% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 25.9% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.6% vs 2.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 3.1% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 6.6% vs 3.1% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 45.9% vs 17.6% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 39.2% vs 31.4% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 17.6% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 40.5% vs 31.4% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 20.6% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 36.5% vs 21.6% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 69.8% vs 7.7% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 45.9% vs 10.2% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 50.8% vs 6.8% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 62.3% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 29.5% vs 8.5% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 36.1% vs 6.8% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 54.7% vs 1.9% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 31.1% vs 5.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 32.1% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 18.0% vs 1.7% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 25% vs 2.9% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 15% vs 2.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 57.7% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 50% vs 7.1% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 27.0% vs 8.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 20.3% vs 2.9% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 26.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 4.0% vs 2.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 45.1% vs 13.3% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 50.7% vs 6.2% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 42.0% vs 6.2% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 29.0% vs 3.1% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 18.8% vs 3.1% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 31.4% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 47.8% vs 31.4% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 41.8% vs 21.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 36.3% vs 17.4% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 32.5% vs 17.4% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 27.5% vs 8.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 7.7% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 54.4% vs 17.6% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 46.7% vs 31.4% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 59.6% vs 17.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 48% vs 31.4% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 56.1% vs 20.6% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 21.6% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 72.2% vs 7.7% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 50.9% vs 10.2% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 44% vs 17.4% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 43.9% vs 6.8% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 66.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 49.1% vs 8.5% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 41.3% vs 17.4% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 30.4% vs 13.3% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 42.1% vs 6.8% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 8.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 53.6% vs 6.2% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 1.9% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 40.4% vs 5.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 26.7% vs 2.9% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 42.0% vs 6.2% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 22.2% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 17.5% vs 1.7% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 17.3% vs 2.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 23.2% vs 3.1% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 8.7% vs 3.1% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 44.1% vs 17.6% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 34.5% vs 31.4% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 44.1% vs 17.6% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 45.5% vs 31.4% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 38.2% vs 20.6% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 43.6% vs 21.6% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 26.4% vs 7.7% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 25.5% vs 10.2% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 44.4% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 29.4% vs 17.4% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 6.8% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 37.7% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 21.6% vs 8.5% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 29.6% vs 7.1% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 15.7% vs 6.8% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 29.4% vs 8.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 22.6% vs 1.9% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 13.7% vs 5.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 22.2% vs 3.6% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 16.2% vs 2.9% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 9.4% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 7.8% vs 1.7% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.9% vs 2.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 3.7% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 10.8% vs 17.6% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 44.9% vs 31.4% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 17.6% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 31.4% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 20.6% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 21.6% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 13.5% vs 7.7% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 11.1% vs 10.2% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 32.1% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 22.9% vs 17.4% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 13.0% vs 6.8% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 11.5% vs 1.9% 1 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 13.0% vs 8.5% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 7.1% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 17.1% vs 17.4% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 14.8% vs 6.8% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 10% vs 8.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 9.6% vs 1.9% 1 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 9.3% vs 5.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 10.7% vs 3.6% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 2.9% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 1.9% vs 1.7% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 2.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 67.4% vs 45.7% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 48% vs 42.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 7.1% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 40% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 43.4% vs 39.8% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 39.8% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.8% vs 40.1% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.6% vs 36.7% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.5% vs 42% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.3% vs 31.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.7% vs 41.9% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 27.6% vs 23.2% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.7% vs 40.8% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 41.1% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.2% vs 42% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.2% vs 40.9% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.4% vs 40.8% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.9% vs 38.7% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.7% vs 40.5% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 35.8% vs 35.8% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 29% vs 29.2% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.1% vs 23.8% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.5% vs 18.5% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 13.7% vs 14.4% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 6.9% vs 7.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 3.6% vs 3.8% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.1% vs 1.9% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.2% vs 0.5% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 39.8% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.7% vs 39.8% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 45.9% vs 40.1% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.2% vs 36.7% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.2% vs 42% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.5% vs 31.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.8% vs 41.9% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 31% vs 23.2% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.3% vs 40.8% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.3% vs 41.1% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.8% vs 42% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 42% vs 40.9% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.9% vs 40.8% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.4% vs 38.7% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 39.7% vs 40.5% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 33% vs 35.8% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.4% vs 29.2% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 23.8% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.6% vs 18.5% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 14.4% vs 14.4% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 7.1% vs 7.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 4.7% vs 3.8% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1.4% vs 1.9% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.4% vs 0.5% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467

ACR70

baricitinib
24.2% vs 7.9%+16.3 vs placebo4 mg · wk 24 · n 227NCT01721057
17 other results
  • 16.9% vs 3.4% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 18.1% vs 3.1% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 11.3% vs 2.3% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 25.3% vs 7.9% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 13.2% vs 3.4% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 17.9% vs 3.1% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 12.6% vs 2.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 42.1% vs 25.2% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 46% vs 25.2% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 42.1% vs 21.4% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 39.5% vs 21.4% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 30.8% vs 15.7% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 33.5% vs 15.7% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 29% vs 0% 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 29% vs 0% 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 21% vs 0% 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 13% vs 0% 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
tofacitinib
25.4% vs 12.1%vs MTX5 mg BID · wk 24 · n 366NCT01039688
271 other results
  • 37.3% vs 12.1% 10 mg BID · wk 24 · n 391 · Phase 3 · primary NCT01039688
  • 13.2% vs 3.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 19.9% vs 1.9% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 14.6% vs 1.3% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 11.9% vs 3.2% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 15.3% vs 5.8% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 8.4% vs 1.9% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 12.2% vs 1.9% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 10.7% vs 2.6% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 13.6% vs 1.5% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 10.0% vs 3.3% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 9% vs 1.3% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 5.0% vs 1.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 3.5% vs 0% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 2.6% vs 0.9% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.9% vs 0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 7.6% vs 0% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 2.1% vs 0% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 0.3% vs 0% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 16.2% vs 3.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 21.9% vs 1.9% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 22.3% vs 1.3% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 18.1% vs 3.2% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 20.3% vs 5.8% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 14.2% vs 1.9% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 14.8% vs 1.9% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 17.1% vs 2.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 10.5% vs 1.5% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 19.0% vs 3.3% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 10.4% vs 1.3% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 9.1% vs 1.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 7.1% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 4.1% vs 0.9% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.6% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 6.8% vs 0% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 4.6% vs 0% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 2.3% vs 0% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 23.0% vs 16.6% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 28.7% vs 15.4% 5 mg BID · wk 52 · n 366 · Phase 3 · secondary NCT01039688
  • 18.4% vs 11.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 29.2% vs 13.2% 5 mg BID · wk 39 · n 366 · Phase 3 · secondary NCT01039688
  • 30.1% vs 17.0% 5 mg BID · wk 65 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 15.9% 5 mg BID · wk 78 · n 366 · Phase 3 · secondary NCT01039688
  • 19.9% vs 5.5% 5 mg BID · wk 13 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 17.6% 5 mg BID · wk 91 · n 366 · Phase 3 · secondary NCT01039688
  • 16.2% vs 3.3% 5 mg BID · wk 8.67 · n 366 · Phase 3 · secondary NCT01039688
  • 5.2% vs 0.6% 5 mg BID · wk 4.33 · n 366 · Phase 3 · secondary NCT01039688
  • 34.1% vs 15.4% 5 mg BID · wk 104 · n 366 · Phase 3 · secondary NCT01039688
  • 23.5% vs 16.6% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 15.4% 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • 21.9% vs 11.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 13.2% 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • 37.9% vs 17.0% 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • 36.6% vs 15.9% 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • 26.6% vs 5.5% 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • 36.8% vs 17.6% 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • 23.0% vs 3.3% 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • 9.2% vs 0.6% 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • 37.6% vs 15.4% 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • 22.4% vs 11.8% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 21.1% vs 9.8% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 18.4% vs 8.8% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 23.9% vs 13.7% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 20.4% vs 0% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 18.3% vs 9.8% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 26.9% vs 1.9% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 14.3% vs 3.4% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 18.3% vs 5.8% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 16.3% vs 1.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 25% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 5.8% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 8.9% vs 8.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 4.1% vs 1.7% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 16.9% vs 4.3% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 13.1% vs 3.1% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 17.3% vs 0% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 1.7% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 14.8% vs 0% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 0% vs 1.4% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 1.5% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 1.9% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 11.1% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 4.9% vs 1.5% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 1.6% vs 0% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 37.7% vs 11.8% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 31.1% vs 8.8% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 24.3% vs 13.7% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.5% vs 0% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 49.1% vs 1.9% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 24.6% vs 3.4% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 12.2% vs 5.8% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 37.7% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 16.2% vs 5.8% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 9.5% vs 4.3% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 26.4% vs 0% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 11.5% vs 1.7% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 9.4% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 3.3% vs 0% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 27.4% vs 8.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 27.5% vs 3.1% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 21.7% vs 1.5% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 10.1% vs 1.5% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 28.4% vs 9.8% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 28.4% vs 13.7% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 22.4% vs 9.8% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 23.8% vs 5.8% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 17.5% vs 5.8% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 4.3% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 1.4% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 2.5% vs 0% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 26.2% vs 1.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 18.0% vs 1.7% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 26.9% vs 3.6% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 19.7% vs 1.7% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 7.7% vs 0% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 14.9% vs 1.4% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 33.3% vs 11.8% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 9.8% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 31.6% vs 8.8% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 28% vs 13.7% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 33.3% vs 0% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 9.8% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 51.9% vs 1.9% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 26.3% vs 3.4% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 5.8% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 21.1% vs 1.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 40.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 24.6% vs 1.7% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 5.8% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 14.3% vs 8.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 17.5% vs 1.7% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 4.3% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 21.7% vs 3.1% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 16.7% vs 0% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 8.8% vs 1.7% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 13.3% vs 1.4% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 17.4% vs 1.5% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 7.4% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 6.7% vs 0% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 4.3% vs 1.5% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 23.5% vs 11.8% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 23.6% vs 9.8% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 8.8% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 29.1% vs 13.7% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 26.5% vs 0% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 21.8% vs 9.8% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 13.2% vs 1.9% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 11.8% vs 3.4% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.6% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 20.6% vs 5.8% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 7.8% vs 1.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 3.9% vs 1.7% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 3.6% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 14.7% vs 5.8% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 2.0% vs 1.7% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 4.3% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 3.8% vs 0% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 5.9% vs 1.7% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 7.3% vs 1.4% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 3.7% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.5% vs 0% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 8.1% vs 11.8% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 9.8% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 8.8% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 20.4% vs 13.7% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 0% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 16.3% vs 9.8% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 7.5% vs 1.9% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 5.6% vs 3.4% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 3.6% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 5.8% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 5.7% vs 1.9% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 9.3% vs 1.7% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 3.6% vs 3.6% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 8.6% vs 5.8% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 1.4% vs 4.3% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 0% vs 1.7% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 0% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 1.9% vs 0% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 34.8% vs 30.4% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 20% vs 19.1% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 3.6% vs 0% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 2.9% vs 1.4% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 6.7% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 23.2% vs 19.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.5% vs 20.1% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.7% vs 21% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.4% vs 16.1% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.6% vs 22.4% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.4% vs 13.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 22.2% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 7.8% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 24% vs 22.6% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.7% vs 23.6% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.4% vs 24.7% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.5% vs 24.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 24.2% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.5% vs 23.3% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.8% vs 23.6% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 21.5% vs 20.5% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.6% vs 16.4% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 14.8% vs 13.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.9% vs 11% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 8.8% vs 8.1% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.4% vs 6.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 4% vs 4.4% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.7% vs 2.4% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.5% vs 1% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.1% vs 0.3% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.6% vs 19.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.2% vs 20.1% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 21% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 22.7% vs 16.1% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.2% vs 22.4% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.4% vs 13.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.4% vs 22.2% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.3% vs 7.8% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.5% vs 22.6% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 23.6% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.3% vs 24.7% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.9% vs 24.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.6% vs 24.2% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 24.8% vs 23.3% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.5% vs 23.6% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 20.5% vs 20.5% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 15.7% vs 16.4% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.4% vs 13.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 8.7% vs 8.1% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 5.7% vs 6.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 3.9% vs 4.4% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.6% vs 2.4% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 1% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.3% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467

DAS28-CRP remission

baricitinib
—Trial running · NCT04870203
tofacitinib
23.0% vs 5.2%+17.8 vs placebo5 mg · wk 26 · n 309NCT00847613
174 other results
  • 20.4% vs 5.2% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 11.3% vs 2.0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 36.4% vs 5.2% 10 mg · wk 26 · n 308 · Phase 3 · secondary NCT00847613
  • 26.9% vs 5.2% 10 mg · wk 13 · n 308 · Phase 3 · secondary NCT00847613
  • 9.1% vs 2.0% 10 mg · wk 4.33 · n 308 · Phase 3 · secondary NCT00847613
  • 38.4% vs 18.5% 5 mg BID · wk 104 · n 367 · Phase 3 · secondary NCT01039688
  • 37.1% vs 17.4% 5 mg BID · wk 91 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 19.0% 5 mg BID · wk 78 · n 367 · Phase 3 · secondary NCT01039688
  • 37.6% vs 19.6% 5 mg BID · wk 65 · n 367 · Phase 3 · secondary NCT01039688
  • 36.5% vs 20.6% 5 mg BID · wk 52 · n 367 · Phase 3 · secondary NCT01039688
  • 36.2% vs 17.4% 5 mg BID · wk 39 · n 367 · Phase 3 · secondary NCT01039688
  • 31.3% vs 15.2% 5 mg BID · wk 26 · n 367 · Phase 3 · secondary NCT01039688
  • 25.9% vs 9.8% 5 mg BID · wk 13 · n 367 · Phase 3 · secondary NCT01039688
  • 20.4% vs 5.4% 5 mg BID · wk 8.67 · n 367 · Phase 3 · secondary NCT01039688
  • 7.4% vs 2.7% 5 mg BID · wk 4.33 · n 367 · Phase 3 · secondary NCT01039688
  • 43.9% vs 18.5% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 17.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 19.0% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 19.6% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 49.5% vs 20.6% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 45.7% vs 17.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 47.2% vs 15.2% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 37.8% vs 9.8% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 28.7% vs 5.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 14.1% vs 2.7% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 65.9% vs 30% 5 mg · wk 24 · n 40 · Phase 2 · secondary NCT00550446
  • 22% vs 15% 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • 41.5% vs 19.4% 5 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 68.9% vs 16.7% 5 mg · wk 20 · n 40 · Phase 2 · secondary NCT00550446
  • 20% vs 5.6% 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • 35.1% vs 13.9% 5 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 69.6% vs 35% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT00550446
  • 28.3% vs 15% 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • 24.1% vs 8.1% 5 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 6.7% 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT00550446
  • 24.4% vs 6.7% 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • 16.7% vs 6.7% 5 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 65.8% vs 3.3% 5 mg · wk 10 · n 40 · Phase 2 · secondary NCT00550446
  • 21.7% vs 4.3% 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • 66.7% vs 9.7% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT00550446
  • 14.9% vs 4.4% 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • 19.4% vs 6.9% 5 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 56.4% vs 5.9% 5 mg · wk 6 · n 40 · Phase 2 · secondary NCT00550446
  • 8.9% vs 1.9% 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • 13.6% vs 3.5% 5 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT00550446
  • 4.4% vs 1.9% 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • 8.1% vs 3.3% 5 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 62.5% vs 2.7% 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT00550446
  • 4.2% vs 0% 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 5 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 72.7% vs 30% 10 mg · wk 24 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT00550446
  • 36.5% vs 19.4% 10 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 88.7% vs 16.7% 10 mg · wk 20 · n 45 · Phase 2 · secondary NCT00550446
  • 43.4% vs 5.6% 10 mg · wk 20 · n 60 · Phase 2 · secondary NCT00550446
  • 37.1% vs 13.9% 10 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 78.2% vs 35% 10 mg · wk 16 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 16 · n 60 · Phase 2 · secondary NCT00550446
  • 30.2% vs 8.1% 10 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 75.6% vs 6.7% 10 mg · wk 12 · n 45 · Phase 2 · secondary NCT00550446
  • 33.3% vs 6.7% 10 mg · wk 12 · n 60 · Phase 2 · secondary NCT00550446
  • 32.3% vs 6.7% 10 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 90.7% vs 3.3% 10 mg · wk 10 · n 45 · Phase 2 · secondary NCT00550446
  • 31.6% vs 4.3% 10 mg · wk 10 · n 60 · Phase 2 · secondary NCT00550446
  • 78.6% vs 9.7% 10 mg · wk 8 · n 45 · Phase 2 · secondary NCT00550446
  • 21.4% vs 4.4% 10 mg · wk 8 · n 60 · Phase 2 · secondary NCT00550446
  • 21.3% vs 6.9% 10 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 79.5% vs 5.9% 10 mg · wk 6 · n 45 · Phase 2 · secondary NCT00550446
  • 24.1% vs 1.9% 10 mg · wk 6 · n 60 · Phase 2 · secondary NCT00550446
  • 24.2% vs 3.5% 10 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 83.7% vs 5.7% 10 mg · wk 4 · n 45 · Phase 2 · secondary NCT00550446
  • 17.5% vs 1.9% 10 mg · wk 4 · n 60 · Phase 2 · secondary NCT00550446
  • 19.1% vs 3.3% 10 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 71.1% vs 2.7% 10 mg · wk 2 · n 45 · Phase 2 · secondary NCT00550446
  • 5% vs 0% 10 mg · wk 2 · n 60 · Phase 2 · secondary NCT00550446
  • 4.4% vs 3.3% 10 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 32.7% vs 19.4% 20 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 30.9% vs 13.9% 20 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.1% vs 8.1% 20 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 24.6% vs 6.7% 20 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 20.9% vs 6.9% 20 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 10.1% vs 3.5% 20 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 10% vs 3.3% 20 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 4.0% vs 3.3% 20 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 84.6% vs 30% 15 mg · wk 24 · n 39 · Phase 2 · secondary NCT00550446
  • 50% vs 15% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 39.3% vs 19.4% 15 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 76.9% vs 16.7% 15 mg · wk 20 · n 39 · Phase 2 · secondary NCT00550446
  • 42.3% vs 5.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 38.6% vs 13.9% 15 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 82.4% vs 35% 15 mg · wk 16 · n 39 · Phase 2 · secondary NCT00550446
  • 43.1% vs 15% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 37.9% vs 8.1% 15 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 68.6% vs 6.7% 15 mg · wk 12 · n 39 · Phase 2 · secondary NCT00550446
  • 40.4% vs 6.7% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 37.1% vs 6.7% 15 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 79.4% vs 3.3% 15 mg · wk 10 · n 39 · Phase 2 · secondary NCT00550446
  • 38.5% vs 4.3% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 75% vs 9.7% 15 mg · wk 8 · n 39 · Phase 2 · secondary NCT00550446
  • 41.5% vs 4.4% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 23.9% vs 6.9% 15 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 67.6% vs 5.9% 15 mg · wk 6 · n 39 · Phase 2 · secondary NCT00550446
  • 32.7% vs 1.9% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 22.7% vs 3.5% 15 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 15 mg · wk 4 · n 39 · Phase 2 · secondary NCT00550446
  • 15.1% vs 1.9% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 16.9% vs 3.3% 15 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 66.7% vs 2.7% 15 mg · wk 2 · n 39 · Phase 2 · secondary NCT00550446
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 13.2% vs 3.3% 15 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 46.4% vs 30% 3 mg · wk 24 · n 33 · Phase 2 · secondary NCT00550446
  • 39.3% vs 15% 3 mg · wk 24 · n 50 · Phase 2 · secondary NCT00550446
  • 35.7% vs 19.4% 3 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 58.6% vs 16.7% 3 mg · wk 20 · n 33 · Phase 2 · secondary NCT00550446
  • 20.7% vs 5.6% 3 mg · wk 20 · n 50 · Phase 2 · secondary NCT00550446
  • 43.2% vs 13.9% 3 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 35% 3 mg · wk 16 · n 33 · Phase 2 · secondary NCT00550446
  • 30% vs 15% 3 mg · wk 16 · n 50 · Phase 2 · secondary NCT00550446
  • 41.9% vs 8.1% 3 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 42.9% vs 6.7% 3 mg · wk 12 · n 33 · Phase 2 · secondary NCT00550446
  • 8.9% vs 6.7% 3 mg · wk 12 · n 50 · Phase 2 · secondary NCT00550446
  • 30.9% vs 6.7% 3 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 3.3% 3 mg · wk 10 · n 33 · Phase 2 · secondary NCT00550446
  • 8.5% vs 4.3% 3 mg · wk 10 · n 50 · Phase 2 · secondary NCT00550446
  • 46.7% vs 9.7% 3 mg · wk 8 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 4.4% 3 mg · wk 8 · n 50 · Phase 2 · secondary NCT00550446
  • 22.0% vs 6.9% 3 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 43.3% vs 5.9% 3 mg · wk 6 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 1.9% 3 mg · wk 6 · n 50 · Phase 2 · secondary NCT00550446
  • 19.7% vs 3.5% 3 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 5.7% 3 mg · wk 4 · n 33 · Phase 2 · secondary NCT00550446
  • 6.5% vs 1.9% 3 mg · wk 4 · n 50 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.3% 3 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 2.7% 3 mg · wk 2 · n 33 · Phase 2 · secondary NCT00550446
  • 4% vs 0% 3 mg · wk 2 · n 50 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.3% 3 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 30% 1 mg · wk 24 · n 43 · Phase 2 · secondary NCT00550446
  • 16.7% vs 15% 1 mg · wk 24 · n 53 · Phase 2 · secondary NCT00550446
  • 23.1% vs 19.4% 1 mg · wk 24 · n 64 · Phase 2 · secondary NCT00413660
  • 46.2% vs 16.7% 1 mg · wk 20 · n 43 · Phase 2 · secondary NCT00550446
  • 19.2% vs 5.6% 1 mg · wk 20 · n 53 · Phase 2 · secondary NCT00550446
  • 20.5% vs 13.9% 1 mg · wk 20 · n 64 · Phase 2 · secondary NCT00413660
  • 48.1% vs 35% 1 mg · wk 16 · n 43 · Phase 2 · secondary NCT00550446
  • 22.2% vs 15% 1 mg · wk 16 · n 53 · Phase 2 · secondary NCT00550446
  • 14.3% vs 8.1% 1 mg · wk 16 · n 64 · Phase 2 · secondary NCT00413660
  • 22.2% vs 6.7% 1 mg · wk 12 · n 43 · Phase 2 · secondary NCT00550446
  • 9.3% vs 6.7% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00550446
  • 6.6% vs 6.7% 1 mg · wk 12 · n 64 · Phase 2 · secondary NCT00413660
  • 26.3% vs 3.3% 1 mg · wk 10 · n 43 · Phase 2 · secondary NCT00550446
  • 10.9% vs 4.3% 1 mg · wk 10 · n 53 · Phase 2 · secondary NCT00550446
  • 25.6% vs 9.7% 1 mg · wk 8 · n 43 · Phase 2 · secondary NCT00550446
  • 2.1% vs 4.4% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00550446
  • 7.9% vs 6.9% 1 mg · wk 8 · n 64 · Phase 2 · secondary NCT00413660
  • 20.5% vs 5.9% 1 mg · wk 6 · n 43 · Phase 2 · secondary NCT00550446
  • 8.5% vs 1.9% 1 mg · wk 6 · n 53 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.5% 1 mg · wk 6 · n 64 · Phase 2 · secondary NCT00413660
  • 30% vs 5.7% 1 mg · wk 4 · n 43 · Phase 2 · secondary NCT00550446
  • 6% vs 1.9% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00550446
  • 4.6% vs 3.3% 1 mg · wk 4 · n 64 · Phase 2 · secondary NCT00413660
  • 25.6% vs 2.7% 1 mg · wk 2 · n 43 · Phase 2 · secondary NCT00550446
  • 1.9% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 1 mg · wk 2 · n 64 · Phase 2 · secondary NCT00413660
  • 16.7% vs 19.4% 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • 0% vs 13.9% 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • 11.1% vs 8.1% 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • 15.4% vs 19.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 15.4% vs 13.9% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 23.1% vs 8.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 25% vs 19.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 28.6% vs 13.9% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 9.5% vs 8.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 24% vs 22.4% 11mg MR · wk 24 · n 100 · Phase 2 · secondary NCT04413617
  • 40.8% vs 22.4% 400mg MR + 11mg MR · wk 24 · n 103 · Phase 2 · secondary NCT04413617

HAQ-DI, change

baricitinib
-0.5 vs -0.3−0.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • -0.4 vs -0.2 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • -0.5 vs -0.3 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • -0.4 vs -0.2 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • -0.7 vs -0.3 wk 12 · n 487 · Phase 3 · secondary NCT01710358
  • -0.6 vs -0.3 wk 12 · n 144 · Phase 3 · secondary NCT02265705
  • -1.0 vs -0.7 wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • -0.9 vs -0.7 wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • -0.5 vs -0.1 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.3 vs -0.1 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
tofacitinib
-0.5 vs -0.2−0.3 vs placebo5 mg · wk 13 · n 240NCT00814307
233 other results
  • -0.5 vs -0.2 5 mg · wk 13 · n 311 · Phase 3 · primary NCT00856544
  • -0.5 vs -0.2 5 mg twice daily · wk 13 · n 201 · Phase 3 · primary NCT00853385
  • -0.3 vs -0.1 5 mg · wk 13 · n 315 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 5 mg · wk 13 · n 132 · Phase 3 · primary NCT00960440
  • -0.5 vs -0.2 10 mg · wk 13 · n 241 · Phase 3 · primary NCT00814307
  • -0.5 vs -0.2 10 mg · wk 13 · n 315 · Phase 3 · primary NCT00856544
  • -0.6 vs -0.2 10 mg twice daily · wk 13 · n 199 · Phase 3 · primary NCT00853385
  • -0.4 vs -0.1 10 mg · wk 13 · n 309 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 10 mg · wk 13 · n 134 · Phase 3 · primary NCT00960440
  • -0.8 vs -0.6 5 mg BID · wk 26 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 5 mg BID · wk 13 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.7 5 mg BID · wk 39 · n 365 · Phase 3 · secondary NCT01039688
  • -0.7 vs -0.3 5 mg BID · wk 8.67 · n 365 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.2 5 mg BID · wk 4.33 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 52 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 65 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 78 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 91 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 104 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.6 10 mg BID · wk 26 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.3 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • -0.6 vs -0.2 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • -1 vs -0.7 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.4 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.3 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 5 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs 0.2 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 5 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.2 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.2 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.0 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 5 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 5 mg BID · wk 8 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.2 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 5 mg BID · wk 6 · n 59 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.0 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 5 mg BID · wk 4 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs 0.1 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • -0.2 vs -0.0 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.0 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 5 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 5 mg BID · wk 2 · n 59 · Phase 2 · secondary NCT00147498
  • -0.1 vs 0 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg BID · wk 1 · n 59 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.4 10 mg · wk 24 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 20 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 16 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.3 10 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.2 10 mg · wk 12 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.2 10 mg · wk 10 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.5 vs -0.2 10 mg · wk 8 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.2 10 mg · wk 6 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 10 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.1 10 mg · wk 4 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.1 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 10 mg · wk 2 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 20 mg · wk 4 · n 79 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.1 20 mg · wk 2 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 10 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.0 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 10 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 30 mg BID · wk 8 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 30 mg BID · wk 6 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.1 30 mg BID · wk 4 · n 64 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.1 30 mg BID · wk 2 · n 64 · Phase 2 · secondary NCT00147498
  • -0.4 vs -0.1 30 mg BID · wk 1 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.4 20 mg · wk 24 · n 79 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.4 20 mg · wk 20 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 20 mg · wk 16 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 20 mg · wk 8 · n 79 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 20 mg · wk 6 · n 79 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • -0.8 vs -0.4 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 15 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • -0.8 vs -0.2 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 15 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.8 vs -0.2 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • -0.7 vs -0.2 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 15 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 15 mg BID · wk 8 · n 68 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 15 mg BID · wk 6 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs 0.0 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.1 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 15 mg BID · wk 4 · n 68 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.1 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.0 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 15 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 15 mg BID · wk 2 · n 68 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.1 15 mg BID · wk 1 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs -0.4 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 3 mg · wk 24 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 3 mg · wk 20 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.3 3 mg · wk 16 · n 66 · Phase 2 · secondary NCT00413660
  • -0.4 vs 0.2 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 3 mg · wk 12 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.2 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs 0.0 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 8 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 6 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0.0 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 4 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.0 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 3 mg · wk 2 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.6 vs -0.4 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 1 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.2 vs 0.2 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 1 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs 0.2 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.0 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 1 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 1 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.0 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.1 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 1 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.0 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • -0.1 vs -0.0 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • -0.1 vs -0.1 1 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • 0.1 vs -0.1 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • -0.4 vs -0.0 wk 6 · n 93 · Phase 1 · secondary NCT01484561
  • -0.5 vs -0.4 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.4 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.4 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.3 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.3 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.5 5 mg BID · wk 26 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 5 mg BID · wk 13 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 39 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.4 vs -0.4 5 mg BID · wk 8.67 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 52 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 65 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 78 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 91 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 104 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 117 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 130 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 143 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 156 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 169 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 182 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 195 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 208 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 221 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 234 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 247 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 260 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 273 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 26 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 13 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 39 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 8.67 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 52 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 65 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 78 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 91 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 104 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 117 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 130 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 143 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 156 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 169 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 182 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 195 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 208 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 221 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 234 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 247 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 260 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 273 · n 1390 · Phase 4 · secondary NCT02092467

Modified Sharp score, change

baricitinib
0.3 vs 0.8−0.5 vs placebowk 24 · n 470NCT01710358
2 other results
  • 0.4 vs 0.6 wk 24 · n 152 · Phase 3 · secondary NCT01711359
  • 0.3 vs 0.6 wk 24 · n 198 · Phase 3 · secondary NCT01711359
tofacitinib
0.1 vs 0.5−0.3 vs placebo5 mg · wk 26 · n 286NCT00847613
7 other results
  • 0.1 vs 0.5 10 mg · wk 26 · n 295 · Phase 3 · primary NCT00847613
  • 0.2 vs 0.7 5 mg BID · wk 24 · n 346 · Phase 3 · primary NCT01039688
  • 0.1 vs 0.7 10 mg BID · wk 24 · n 370 · Phase 3 · primary NCT01039688
  • 0.4 vs 1.2 5 mg BID · wk 52 · n 346 · Phase 3 · secondary NCT01039688
  • 0.6 vs 2.1 5 mg BID · wk 104 · n 346 · Phase 3 · secondary NCT01039688
  • 0.2 vs 1.2 10 mg BID · wk 52 · n 371 · Phase 3 · secondary NCT01039688
  • 0.3 vs 2.1 10 mg BID · wk 104 · n 371 · Phase 3 · secondary NCT01039688
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. baricitinib: 11 of 11 rows · tofacitinib: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbaricitinib
Rows use multiple source trials
tofacitinib
Rows use multiple source trials
Boolean Remission
responder rate · % of participants
15.6% (n=487) vs NA placebo @ 52wka,b,c
NCT01710358 · Phase 3
2 other source trials
17% (n=159) vs 11.4% (n=210) Methotrexate @ 52wk
NCT01711359 · Phase 3
20.9% (n=215) vs 11.4% (n=210) Methotrexate @ 52wk
NCT01711359 · Phase 3 · combination
11.22% (n=1455) vs 9.12% (n=1451) TNFi @ 52wk5 mg BIDd,a,b,c
NCT02092467 · Phase 4
show 1 more dose
13.06% (n=1456) vs 9.12% (n=1451) TNFi @ 52wk10 mg BID
NCT02092467 · Phase 4
CDAI
absolute change · score
-26.44 vs NA placebo score @ 52wka,b,c
NCT01710358 · Phase 3
2 other source trials
-28.94 vs -21.95 Methotrexate score @ 52wk
NCT01711359 · Phase 3
-30.72 vs -21.95 Methotrexate score @ 52wk
NCT01711359 · Phase 3 · combination
-28.52 vs -27.73 TNFi score @ 52wk5 mg BIDd,a,b,c
NCT02092467 · Phase 4
show 1 more dose
-29.38 vs -27.73 TNFi score @ 52wk10 mg BID
NCT02092467 · Phase 4
DAS28-CRP
absolute change · score
-2.74 vs -2.01 Methotrexate score @ 24wkd,e,b
NCT01711359 · Phase 3
show 1 more dose
-2.82 vs -2.01 Methotrexate score @ 24wk
NCT01711359 · Phase 3 · combination
-2.66 vs -2.53 PF-06651600 score @ 24wk11mg MRd,e,b
NCT04413617 · Phase 2 · registry result, not featured evidence
show 1 more dose
-3.05 vs -2.53 PF-06651600 score @ 24wk400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
DAS28-ESR
absolute change · score
-2.84 vs -2.32 Methotrexate score @ 52wkd,b
NCT01711359 · Phase 3
show 1 more dose
-3.22 vs -2.32 Methotrexate score @ 52wk
NCT01711359 · Phase 3 · combination
-2.78 vs -2.2 MTX score @ 52wk5 mg BIDd,b
NCT01039688 · Phase 3
show 1 more dose
-3.05 vs -2.2 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
FACIT-Fatigue
absolute change · score
10.8 vs NA placebo score @ 52wkb,c
NCT01710358 · Phase 3
2 other source trials
11.3 vs 9.1 Methotrexate score @ 52wk
NCT01711359 · Phase 3
12.6 vs 9.1 Methotrexate score @ 52wk
NCT01711359 · Phase 3 · combination
8.75 vs 6.89 MTX score @ 52wk5 mg BIDd,b,c
NCT01039688 · Phase 3
show 1 more dose
9.18 vs 6.89 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
SDAI
absolute change · score
-23.78 vs -14.55 placebo score @ 24wk4 mgd,a,b,c,f
NCT01721057 · Phase 3
show 1 more dose
-21.87 vs -14.55 placebo score @ 24wk2 mg
NCT01721057 · Phase 3
-32.27 vs -32.27 TNFi score @ 273wk5 mg BIDd,a,b,c,f
NCT02092467 · Phase 4
show 1 more dose
-32.12 vs -32.27 TNFi score @ 273wk10 mg BID
NCT02092467 · Phase 4
SDAI Remission
responder rate · % of participants
22.6% (n=487) vs NA placebo @ 52wka,b,c
NCT01710358 · Phase 3
15.89% (n=1455) vs 13.92% (n=1451) TNFi @ 52wk5 mg BIDd,a,b,c
NCT02092467 · Phase 4
show 1 more dose
18.69% (n=1456) vs 13.92% (n=1451) TNFi @ 52wk10 mg BID
NCT02092467 · Phase 4
Dropout rate
5.9%Baricitinibg
NCT01710358 · Phase 3
show 43 more results
—Baricitinib Follow-up
NCT01710358 · Phase 3
—Baricitinib Treatment A
NCT01710358 · Phase 3
—BaricitinibTreatment B
NCT01710358 · Phase 3
15%Baricitinib
NCT01711359 · Phase 3
19.5%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
—Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
—Baricitinib - Follow-up
NCT01711359 · Phase 3
6.2%4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
—4 mg
NCT01469013 · Phase 2
—2 mg
NCT01469013 · Phase 2
—8 mg
NCT01469013 · Phase 2
—1 mg
NCT01469013 · Phase 2
—4 mg
NCT01721057 · Phase 3
10.1%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
8.3%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
10.7%4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
9.8%2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
51.7%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
51.1%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
55.7%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
60.8%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
33.7%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
94.1%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
75.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
70.2%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
95.8%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
100%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
76.9%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
72.8%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
0%g
NCT01262118 · Phase 1
show 80 more results
4.9%5 mg
NCT00814307 · Phase 3
11%10 mg
NCT00814307 · Phase 3
17.9%5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
20.8%10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
26.5%5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
21.4%10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
n/a: no completion milestone5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
n/a: no completion milestone10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
19.5%5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
23.1%10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—5 mg BID
NCT01039688 · Phase 3
28%10 mg BID
NCT01039688 · Phase 3
27.7%5 mg BID
NCT02092467 · Phase 4
31.5%10 mg BID
NCT02092467 · Phase 4
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
10.2%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
56.9%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
50.8%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
3.8%
NCT02281552 · Phase 3 · registry result, not featured evidence
36.6%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.1%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
6.9%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
7.8%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
9.1%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
6.3%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00976599 · Phase 2 · registry result, not featured evidence
—
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.5%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.7%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.5%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.8%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
8%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.9%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.3%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
9.6%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
18.5%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
17.9%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
25%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.9%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.1%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
9.9%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
10.7%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
12.5%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
12%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
10.3%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
9.9%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.9%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
24.6%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
13%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
9.3%
NCT01484561 · Phase 1 · registry result, not featured evidence
—CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
—Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
3.7%Baricitinibg
NCT01710358 · Phase 3
show 43 more results
—Baricitinib Follow-up
NCT01710358 · Phase 3
—Baricitinib Treatment A
NCT01710358 · Phase 3
—BaricitinibTreatment B
NCT01710358 · Phase 3
6.3%Baricitinib
NCT01711359 · Phase 3
11.2%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
—Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
—Baricitinib - Follow-up
NCT01711359 · Phase 3
1.4%4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
—4 mg
NCT01469013 · Phase 2
—2 mg
NCT01469013 · Phase 2
—8 mg
NCT01469013 · Phase 2
—1 mg
NCT01469013 · Phase 2
—4 mg
NCT01721057 · Phase 3
5.3%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
4.4%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
5.6%4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
4%2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
13.5%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
12.6%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
8.3%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
5.7%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
6%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
12.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
21.8%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
18.1%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
11.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
10.9%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
14.5%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
16.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—g
NCT01262118 · Phase 1
show 80 more results
1.2%5 mg
NCT00814307 · Phase 3
3.7%10 mg
NCT00814307 · Phase 3
6.3%5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
9.1%10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
11.8%5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
11.9%10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
11.2%5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
8.2%10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
9%5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
9%10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—5 mg BID
NCT01039688 · Phase 3
9.8%10 mg BID
NCT01039688 · Phase 3
—5 mg BID
NCT02092467 · Phase 4
—10 mg BID
NCT02092467 · Phase 4
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
5.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
25.9%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
23.1%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
2.9%
NCT02281552 · Phase 3 · registry result, not featured evidence
25.9%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
22.9%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
1%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
1%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
3.6%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00976599 · Phase 2 · registry result, not featured evidence
—
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
5.7%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
1.9%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.5%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.7%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
14.3%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
14.3%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.1%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.4%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
5.3%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
5%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
8%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.4%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.4%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.6%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
10.1%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
8.7%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1%
NCT01484561 · Phase 1 · registry result, not featured evidence
—CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
—Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
—Baricitinibg
NCT01710358 · Phase 3
show 43 more results
0%Baricitinib Follow-up
NCT01710358 · Phase 3
5.3%Baricitinib Treatment A
NCT01710358 · Phase 3
3.8%BaricitinibTreatment B
NCT01710358 · Phase 3
7.5%Baricitinib
NCT01711359 · Phase 3
7.9%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
0%Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
0%Baricitinib - Follow-up
NCT01711359 · Phase 3
2.8%4 mg
NCT02265705 · Phase 3
1.7%4 mg
NCT02265705 · Phase 3
2.5%4 mg
NCT02265705 · Phase 3
9.5%Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
0%4 mg
NCT01469013 · Phase 2
4.2%2 mg
NCT01469013 · Phase 2
4.2%8 mg
NCT01469013 · Phase 2
0%1 mg
NCT01469013 · Phase 2
5.3%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
4.5%4 mg
NCT01721057 · Phase 3
2.6%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
0%2 mg
NCT01721057 · Phase 3
—4 mg
NCT01721044 · Phase 3
0%4 mg
NCT01721044 · Phase 3
10.7%4 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
11.1%2 mg
NCT01721044 · Phase 3
4.6%2 mg
NCT01721044 · Phase 3
31.3%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
29.5%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
23.7%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
22.9%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
20%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
30%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
37.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
27.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
0%g
NCT01262118 · Phase 1
show 80 more results
—5 mg
NCT00814307 · Phase 3
—10 mg
NCT00814307 · Phase 3
—5 mg
NCT00856544 · Phase 3
1.6%5 mg
NCT00856544 · Phase 3
2.2%5 mg
NCT00856544 · Phase 3
2.9%5 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
2.2%10 mg
NCT00856544 · Phase 3
2.8%10 mg
NCT00856544 · Phase 3
2.5%10 mg
NCT00856544 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
4.3%5 mg twice daily
NCT00853385 · Phase 3
4.2%5 mg twice daily
NCT00853385 · Phase 3
5.9%5 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
3.2%10 mg twice daily
NCT00853385 · Phase 3
4%10 mg twice daily
NCT00853385 · Phase 3
5%10 mg twice daily
NCT00853385 · Phase 3
—5 mg
NCT00847613 · Phase 3
5%5 mg
NCT00847613 · Phase 3
3.5%5 mg
NCT00847613 · Phase 3
3.7%5 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
2.3%10 mg
NCT00847613 · Phase 3
3.3%10 mg
NCT00847613 · Phase 3
3.2%10 mg
NCT00847613 · Phase 3
—5 mg
NCT00960440 · Phase 3
4%5 mg
NCT00960440 · Phase 3
1.5%5 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
4%10 mg
NCT00960440 · Phase 3
1.5%10 mg
NCT00960440 · Phase 3
10.7%5 mg BID
NCT01039688 · Phase 3
10.8%10 mg BID
NCT01039688 · Phase 3
25.6%5 mg BID
NCT02092467 · Phase 4
28.8%10 mg BID
NCT02092467 · Phase 4
3.8%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
1.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
2.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
10.4%5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
30.8%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
29.7%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
4.8%
NCT02281552 · Phase 3 · registry result, not featured evidence
29.1%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
26.7%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
2.9%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
0%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
5.5%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
3.6%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00976599 · Phase 2 · registry result, not featured evidence
0%
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.8%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
1.9%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
5.7%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.6%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
7%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.9%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.4%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.7%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.7%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.6%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.6%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.4%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
6%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0%20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
8%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
7.3%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0%3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
2%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.8%1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.6%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
4.3%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
7.2%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
2.1%
NCT01484561 · Phase 1 · registry result, not featured evidence
0%CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
0%Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
g
alanine aminotransferase increased 0% (placebo 0%)
anaemia 0% (placebo 0%)
back pain 0% (placebo 0%)
NCT01710358 · Phase 3
show 30 more results
nasopharyngitis 7.6% (placebo 6.1%)
urinary tract infection 4.3% (placebo 0%)
bronchitis 3.9% (placebo 0%)
NCT01710358 · Phase 3
nasopharyngitis 5.7% (placebo 6.1%)
upper respiratory tract infection 3.1% (placebo 0%)
bronchitis 2.8% (placebo 0%)
NCT01710358 · Phase 3
nasopharyngitis 10.1%
upper respiratory tract infection 7.5%
gastroenteritis 6.3%
NCT01711359 · Phase 3
nasopharyngitis 9.8%
nausea 9.3%
upper respiratory tract infection 7.4%
NCT01711359 · Phase 3 · combination
abdominal discomfort 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT01711359 · Phase 3 · combination
constipation 6.7%
eczema asteatotic 6.7%
miliaria 6.7%
NCT01711359 · Phase 3
4 mg
upper respiratory tract infection 19.3% (placebo 0%)
hyperlipidaemia 11% (placebo 0%)
urinary tract infection 9% (placebo 0%)
NCT02265705 · Phase 3
4 mg
arthralgia 5.2% (placebo 0%)
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
NCT02265705 · Phase 3
4 mg
upper respiratory tract infection 9.2% (placebo 0%)
hyperlipidaemia 7.5% (placebo 0%)
benign prostatic hyperplasia 7.1% (placebo 0%)
NCT02265705 · Phase 3
blood creatine phosphokinase increased 6.8% (placebo 0%)
upper respiratory tract infection 6.8% (placebo 0%)
nasopharyngitis 5.4% (placebo 0%)
NCT02265705 · Phase 3
4 mg
blood creatine phosphokinase increased 8.3% (placebo 4.1%)
liver function test abnormal 8.3% (placebo 0%)
nasopharyngitis 8.3% (placebo 12.2%)
NCT01469013 · Phase 2
2 mg
hepatic function abnormal 12.5% (placebo 0%)
nasopharyngitis 8.3% (placebo 12.2%)
cystitis 4.2% (placebo 4.1%)
NCT01469013 · Phase 2
8 mg
blood creatine phosphokinase increased 12.5% (placebo 4.1%)
hepatic function abnormal 12.5% (placebo 0%)
hypercholesterolaemia 12.5% (placebo 0%)
NCT01469013 · Phase 2
1 mg
nasopharyngitis 8.3% (placebo 12.2%)
anaemia 4.2% (placebo 0%)
chronic sinusitis 4.2% (placebo 0%)
NCT01469013 · Phase 2
4 mg
upper respiratory tract infection 10.6% (placebo 0%)
nasopharyngitis 7.9% (placebo 0%)
blood creatine phosphokinase increased 6.6% (placebo 5.9%)
NCT01721057 · Phase 3
4 mg
cough 4.5% (placebo 0%)
dyspnoea 4.5% (placebo 0%)
gastritis 4.5% (placebo 0%)
NCT01721057 · Phase 3
2 mg
headache 6.6% (placebo 0%)
upper respiratory tract infection 6.1% (placebo 0%)
urinary tract infection 5.2% (placebo 0%)
NCT01721057 · Phase 3
2 mg
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
acne 0% (placebo 0%)
NCT01721057 · Phase 3
4 mg
cervicitis 5.6% (placebo 0%)
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
NCT01721044 · Phase 3
4 mg
headache 6.8% (placebo 0%)
bronchitis 5.6% (placebo 0%)
nausea 5.6% (placebo 0%)
NCT01721044 · Phase 3
2 mg
cellulitis 11.1% (placebo 0%)
insomnia 11.1% (placebo 0%)
lymphopenia 11.1% (placebo 0%)
NCT01721044 · Phase 3
2 mg
headache 9.8% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 0%)
nasopharyngitis 6.9% (placebo 5.3%)
NCT01721044 · Phase 3
4 mg
covid-19 23.3%
nasopharyngitis 13.8%
urinary tract infection 11.4%
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
2 mg
covid-19 20.8%
nasopharyngitis 11.6%
urinary tract infection 11.3%
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
4 mg
covid-19 8.4%
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
2 mg
covid-19 8.8%
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
4 mg
bronchitis 11.3%
nasopharyngitis 11.3%
upper respiratory tract infection 10.9%
NCT01885078 · Phase 3 · registry result, not featured evidence
4 mg
bronchitis 10.9%
nasopharyngitis 9.8%
influenza 9.4%
NCT01885078 · Phase 3 · registry result, not featured evidence
2 mg
upper respiratory tract infection 19.5%
urinary tract infection 17.8%
bronchitis 16.2%
NCT01885078 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 9.1%
upper respiratory tract infection 7.8%
bronchitis 7.4%
NCT01885078 · Phase 3 · registry result, not featured evidence
g
upper respiratory tract infection 19.4%
headache 11.1%
urinary tract infection 8.3%
NCT01262118 · Phase 1
show 70 more results
5 mg
upper respiratory tract infection 4.1% (placebo 0%)
gastroenteritis 2.2% (placebo 0%)
nasopharyngitis 1.9% (placebo 0%)
NCT00856544 · Phase 3
5 mg
upper respiratory tract infection 3.5% (placebo 0%)
diarrhoea 1.9% (placebo 0%)
sinusitis 1.6% (placebo 2.5%)
NCT00856544 · Phase 3
5 mg
upper respiratory tract infection 6% (placebo 0%)
nasopharyngitis 5.1% (placebo 0%)
diarrhoea 4.4% (placebo 0%)
NCT00856544 · Phase 3
10 mg
nasopharyngitis 2.8% (placebo 0%)
upper respiratory tract infection 2.8% (placebo 0%)
oedema peripheral 2.5% (placebo 1.2%)
NCT00856544 · Phase 3
10 mg
upper respiratory tract infection 5.7% (placebo 0%)
blood creatine phosphokinase increased 2.2% (placebo 0%)
urinary tract infection 2.2% (placebo 1.2%)
NCT00856544 · Phase 3
10 mg
upper respiratory tract infection 7.2% (placebo 0%)
diarrhoea 3.1% (placebo 0%)
headache 3.1% (placebo 2.5%)
NCT00856544 · Phase 3
5 mg twice daily
nasopharyngitis 2.2% (placebo 1.7%)
urinary tract infection 2.2% (placebo 0%)
fall 1.7% (placebo 3.4%)
NCT00853385 · Phase 3
5 mg twice daily
upper respiratory tract infection 3.5% (placebo 0%)
nasopharyngitis 3.1% (placebo 1.7%)
bronchitis 2.7% (placebo 0%)
NCT00853385 · Phase 3
5 mg twice daily
upper respiratory tract infection 4.4% (placebo 0%)
headache 3.9% (placebo 0%)
nasopharyngitis 3.9% (placebo 1.7%)
NCT00853385 · Phase 3
10 mg twice daily
back pain 0.9% (placebo 0%)
fall 0.9% (placebo 3.4%)
nasopharyngitis 0.9% (placebo 1.7%)
NCT00853385 · Phase 3
10 mg twice daily
bronchitis 4% (placebo 0%)
abdominal pain upper 2.8% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT00853385 · Phase 3
10 mg twice daily
upper respiratory tract infection 3.5% (placebo 0%)
headache 3% (placebo 0%)
herpes zoster 2.5% (placebo 0%)
NCT00853385 · Phase 3
5 mg
upper respiratory tract infection 4.7% (placebo 0%)
nasopharyngitis 3.6% (placebo 4.9%)
bronchitis 0.8% (placebo 0%)
NCT00847613 · Phase 3
5 mg
nasopharyngitis 5.5% (placebo 4.9%)
upper respiratory tract infection 3.2% (placebo 0%)
herpes zoster 2.5% (placebo 0%)
NCT00847613 · Phase 3
5 mg
headache 5.6% (placebo 0%)
nasopharyngitis 4.4% (placebo 4.9%)
hypertension 3.4% (placebo 0%)
NCT00847613 · Phase 3
10 mg
bronchitis 2.5% (placebo 0%)
nasopharyngitis 2.5% (placebo 4.9%)
upper respiratory tract infection 2.5% (placebo 0%)
NCT00847613 · Phase 3
10 mg
nasopharyngitis 5.6% (placebo 4.9%)
urinary tract infection 4.3% (placebo 0%)
upper respiratory tract infection 3.8% (placebo 0%)
NCT00847613 · Phase 3
10 mg
nasopharyngitis 4.1% (placebo 4.9%)
cough 2.8% (placebo 0%)
diarrhoea 2.5% (placebo 0%)
NCT00847613 · Phase 3
5 mg
rheumatoid arthritis 3.5% (placebo 3%)
bronchitis 3% (placebo 0%)
nasopharyngitis 3% (placebo 3%)
NCT00960440 · Phase 3
5 mg
diarrhoea 6% (placebo 3.8%)
nasopharyngitis 3.8% (placebo 3%)
upper respiratory tract infection 3.8% (placebo 3%)
NCT00960440 · Phase 3
10 mg
upper respiratory tract infection 4% (placebo 3%)
nasopharyngitis 2.5% (placebo 3%)
back pain 2% (placebo 1.5%)
NCT00960440 · Phase 3
10 mg
headache 6% (placebo 0.8%)
nasopharyngitis 4.5% (placebo 3%)
diarrhoea 3.7% (placebo 3.8%)
NCT00960440 · Phase 3
5 mg BID
upper respiratory tract infection 8%
nasopharyngitis 7.5%
nausea 7.2%
NCT01039688 · Phase 3
10 mg BID
nasopharyngitis 9.8%
blood creatine phosphokinase increased 9.1%
upper respiratory tract infection 9.1%
NCT01039688 · Phase 3
5 mg BID
upper respiratory tract infection 21.9%
bronchitis 15.2%
urinary tract infection 13.1%
NCT02092467 · Phase 4
10 mg BID
upper respiratory tract infection 21.8%
bronchitis 16.7%
urinary tract infection 15.1%
NCT02092467 · Phase 4
11 mg
arthralgia 2.7%
alanine aminotransferase increased 1.9%
aspartate aminotransferase increased 1.9%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
11 mg
alanine aminotransferase increased 3.8%
bronchitis 2.6%
nasopharyngitis 2.6%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
11 mg
nasopharyngitis 5%
upper respiratory tract infection 4.8%
nausea 2.9%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
5 mg
bronchitis 1 6.3%
alanine aminotransferase increased 0%
anemia 0%
NCT00413699 · Phase 3 · registry result, not featured evidence
5 mg BID
upper respiratory tract infection 20.3%
urinary tract infection 14.3%
bronchitis 12.6%
NCT00413699 · Phase 3 · registry result, not featured evidence
10 mg BID
upper respiratory tract infection 18.3%
nasopharyngitis 15.4%
urinary tract infection 13.3%
NCT00413699 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.6%
NCT02281552 · Phase 3 · registry result, not featured evidence
5 mg BID
nasopharyngitis 58%
herpes zoster 15.5%
fall 13.4%
NCT00661661 · Phase 3 · registry result, not featured evidence
10 mg BID
nasopharyngitis 68.6%
herpes zoster 21%
fall 19%
NCT00661661 · Phase 3 · registry result, not featured evidence
11mg MR
sars-cov-2 test positive 6.9%
urinary tract infection 4.9%
headache 3.9%
NCT04413617 · Phase 2 · registry result, not featured evidence
400mg MR + 11mg MR
urinary tract infection 6.8%
sars-cov-2 test positive 3.9%
headache 2.9%
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
5 mg Twice a Day
arthralgia 5.5% (placebo 0%)
rheumatoid arthritis 5.5% (placebo 15.8%)
NCT02147587 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 5.4% (placebo 7.2%)
headache 4.5% (placebo 0.9%)
dizziness 2.7% (placebo 0%)
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
fatigue 13.3% (placebo 0%)
hypoaesthesia 13.3% (placebo 0%)
nausea 13.3% (placebo 7.1%)
NCT00976599 · Phase 2 · registry result, not featured evidence
dyspepsia 4% (placebo 2.1%)
oedema peripheral 4% (placebo 4.3%)
oropharyngeal pain 4% (placebo 0%)
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
5 mg
nasopharyngitis 11.5% (placebo 11.5%)
hypertension 5.8% (placebo 0%)
dental caries 3.8% (placebo 1.9%)
NCT00687193 · Phase 2 · registry result, not featured evidence
10 mg
hyperlipidaemia 11.3% (placebo 0%)
hypercholesterolaemia 5.7% (placebo 0%)
nasopharyngitis 5.7% (placebo 11.5%)
NCT00687193 · Phase 2 · registry result, not featured evidence
15 mg
nasopharyngitis 14.8% (placebo 11.5%)
low density lipoprotein increased 11.1% (placebo 0%)
constipation 5.6% (placebo 3.8%)
NCT00687193 · Phase 2 · registry result, not featured evidence
3 mg
nasopharyngitis 7.5% (placebo 11.5%)
headache 5.7% (placebo 1.9%)
hypercholesterolaemia 3.8% (placebo 0%)
NCT00687193 · Phase 2 · registry result, not featured evidence
1 mg
nasopharyngitis 11.3% (placebo 11.5%)
fall 5.7% (placebo 0%)
abdominal discomfort 3.8% (placebo 1.9%)
NCT00687193 · Phase 2 · registry result, not featured evidence
5 mg
urinary tract infection 10.2% (placebo 5.9%)
diarrhoea 6.1% (placebo 0%)
bronchitis 4.1% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
10 mg
headache 9.8% (placebo 2.9%)
diarrhoea 6.6% (placebo 0%)
hypertension 4.9% (placebo 2.9%)
NCT00550446 · Phase 2 · registry result, not featured evidence
15 mg
urinary tract infection 10.5% (placebo 5.9%)
bronchitis 7% (placebo 0%)
back pain 5.3% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
3 mg
diarrhoea 8.8% (placebo 0%)
back pain 5.9% (placebo 0%)
bronchitis 5.9% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
1 mg
urinary tract infection 8.1% (placebo 5.9%)
diarrhoea 5.4% (placebo 0%)
dizziness 5.4% (placebo 2.9%)
NCT00550446 · Phase 2 · registry result, not featured evidence
5 mg
alanine aminotransferase increased 22.2% (placebo 3.6%)
aspartate aminotransferase increased 14.8% (placebo 3.6%)
stomach discomfort 11.1% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 15.4% (placebo 14.3%)
alanine aminotransferase increased 7.7% (placebo 3.6%)
blood triglycerides increased 7.7% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
3 mg
blood cholesterol increased 11.1% (placebo 0%)
alanine aminotransferase increased 7.4% (placebo 3.6%)
aspartate aminotransferase increased 7.4% (placebo 3.6%)
NCT00603512 · Phase 2 · registry result, not featured evidence
1 mg
nasopharyngitis 10.7% (placebo 14.3%)
headache 7.1% (placebo 3.6%)
stomatitis 7.1% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
5 mg
diarrhoea 12.7% (placebo 3.9%)
nasopharyngitis 7% (placebo 5.9%)
upper respiratory tract infection 7% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
10 mg
cough 8.1% (placebo 0%)
influenza 6.8% (placebo 2%)
nausea 6.8% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
20 mg
headache 13.4% (placebo 2%)
urinary tract infection 9% (placebo 0%)
nasopharyngitis 6% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
20 mg to 5 mg (R)
headache 23.1% (placebo 2%)
upper respiratory tract infection 15.4% (placebo 2%)
abdominal pain upper 7.7% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
15 mg
nasopharyngitis 8% (placebo 5.9%)
alanine aminotransferase increased 6.7% (placebo 2%)
aspartate aminotransferase increased 6.7% (placebo 0%)
NCT00413660 · Phase 2 · registry result, not featured evidence
3 mg
nausea 5.5% (placebo 2%)
pharyngitis 5.5% (placebo 3.9%)
abdominal pain upper 3.6% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
3 mg to 5 mg (R)
upper respiratory tract infection 23.1% (placebo 2%)
arthralgia 15.4% (placebo 0%)
headache 15.4% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
1 mg
diarrhoea 14.3% (placebo 3.9%)
abdominal pain upper 4.1% (placebo 5.9%)
headache 4.1% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
1 mg to 5 mg (R)
gastritis 9.5% (placebo 0%)
nasopharyngitis 9.5% (placebo 5.9%)
oral herpes 9.5% (placebo 0%)
NCT00413660 · Phase 2 · registry result, not featured evidence
5 mg BID
headache 16.4% (placebo 9.2%)
abdominal pain upper 6.6% (placebo 0%)
nausea 6.6% (placebo 4.6%)
NCT00147498 · Phase 2 · registry result, not featured evidence
30 mg BID
headache 24.6% (placebo 9.2%)
leukopenia 10.1% (placebo 1.5%)
nausea 8.7% (placebo 4.6%)
NCT00147498 · Phase 2 · registry result, not featured evidence
15 mg BID
headache 11.6% (placebo 9.2%)
dizziness 5.8% (placebo 1.5%)
hypercholesterolaemia 5.8% (placebo 0%)
NCT00147498 · Phase 2 · registry result, not featured evidence
nasopharyngitis 8.2% (placebo 5.9%)
headache 6.2% (placebo 2%)
nausea 5.2% (placebo 3.9%)
NCT01484561 · Phase 1 · registry result, not featured evidence
nausea 16.7%
arthralgia 8.3%
back pain 8.3%
NCT01745055 · Phase 1 · registry result, not featured evidence
anemia 16.7%
arthralgia 8.3%
back pain 8.3%
NCT01745055 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fAssessment timepoints differ: 273 weeks versus 24 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

baricitinib

ACR50 45% (n=487) vs 16.8% (n=488) placebo @ 12wk
responder rate · % of participants
ACR50 Week 12
NCT01710358 · Phase 3
ACR50 50.5% (n=487) vs 19.3% (n=488) placebo @ 24wk
responder rate · % of participants
ACR50 Week 24
NCT01710358 · Phase 3
ACR50 55.9% (n=487) vs NA placebo @ 52wk
responder rate · % of participants
ACR50 Week 52
NCT01710358 · Phase 3
ACR70 18.9% (n=487) vs 4.7% (n=488) placebo @ 12wk
responder rate · % of participants
ACR70 Week 12
NCT01710358 · Phase 3
ACR70 29.8% (n=487) vs 8% (n=488) placebo @ 24wk
responder rate · % of participants
ACR70 Week 24
NCT01710358 · Phase 3
ACR70 37.2% (n=487) vs NA placebo @ 52wk
responder rate · % of participants
ACR70 Week 52
NCT01710358 · Phase 3
SF-36 Mental Component Summary 3.3 vs 3.2 placebo score @ 12wk
absolute change · score
MCS Week 12
NCT01710358 · Phase 3
SF-36 Mental Component Summary 3.8 vs 2.2 placebo score @ 24wk
absolute change · score
MCS Week 24
NCT01710358 · Phase 3
SF-36 Mental Component Summary 4 vs NA placebo score @ 52wk
absolute change · score
MCS Week 52
NCT01710358 · Phase 3
SF-36 Physical Component Summary 8.9 vs 4.3 placebo score @ 12wk
absolute change · score
PCS Week 12
NCT01710358 · Phase 3
SF-36 Physical Component Summary 9.9 vs 4.6 placebo score @ 24wk
absolute change · score
PCS Week 24
NCT01710358 · Phase 3
SF-36 Physical Component Summary 10.4 vs NA placebo score @ 52wk
absolute change · score
PCS Week 52
NCT01710358 · Phase 3

+ 73 further endpoints in the CSV export.

tofacitinib

DAS28-ESR Remission 6.11% (n=229) vs 4.81% (n=104) placebo @ 12wk5 mg
responder rate · % of participants
NCT00814307 · Phase 3
show 35 more results
9.13% (n=263) vs 2.7% (n=148) placebo @ 24wk5 mg
NCT00856544 · Phase 3
6.21% (n=177) vs 1.09% (n=92) placebo @ 24wk5 mg twice daily
NCT00853385 · Phase 3
7.17% (n=265) vs 1.55% (n=129) placebo @ 24wk5 mg
NCT00847613 · Phase 3
1.55% (n=265) vs 0% (n=129) placebo @ 4.33wk5 mg
NCT00847613 · Phase 3
5.28% (n=265) vs 1.55% (n=129) placebo @ 13wk5 mg
NCT00847613 · Phase 3
7.17% (n=265) vs 1.55% (n=129) placebo @ 26wk5 mg
NCT00847613 · Phase 3
6.72% (n=119) vs 1.67% (n=120) placebo @ 12wk5 mg
NCT00960440 · Phase 3
2.07% (n=342) vs 0% (n=171) MTX @ 4.33wk5 mg BID
NCT01039688 · Phase 3
9.06% (n=342) vs 2.35% (n=171) MTX @ 8.67wk5 mg BID
NCT01039688 · Phase 3
13.74% (n=342) vs 4.68% (n=171) MTX @ 13wk5 mg BID
NCT01039688 · Phase 3
14.62% (n=342) vs 7.6% (n=171) MTX @ 26wk5 mg BID
NCT01039688 · Phase 3
16.37% (n=342) vs 9.94% (n=171) MTX @ 39wk5 mg BID
NCT01039688 · Phase 3
18.71% (n=342) vs 11.7% (n=171) MTX @ 52wk5 mg BID
NCT01039688 · Phase 3
16.37% (n=342) vs 12.87% (n=171) MTX @ 65wk5 mg BID
NCT01039688 · Phase 3
16.96% (n=342) vs 11.11% (n=171) MTX @ 78wk5 mg BID
NCT01039688 · Phase 3
18.42% (n=342) vs 8.77% (n=171) MTX @ 91wk5 mg BID
NCT01039688 · Phase 3
20.76% (n=342) vs 9.94% (n=171) MTX @ 104wk5 mg BID
NCT01039688 · Phase 3
10.05% (n=219) vs 4.81% (n=104) placebo @ 12wk10 mg
NCT00814307 · Phase 3
13.33% (n=270) vs 2.7% (n=148) placebo @ 24wk10 mg
NCT00856544 · Phase 3
12.5% (n=176) vs 1.09% (n=92) placebo @ 24wk10 mg twice daily
NCT00853385 · Phase 3
15.95% (n=257) vs 1.55% (n=129) placebo @ 24wk10 mg
NCT00847613 · Phase 3
2.8% (n=257) vs 0% (n=129) placebo @ 4.33wk10 mg
NCT00847613 · Phase 3
11.28% (n=257) vs 1.55% (n=129) placebo @ 13wk10 mg
NCT00847613 · Phase 3
15.95% (n=257) vs 1.55% (n=129) placebo @ 26wk10 mg
NCT00847613 · Phase 3
11.2% (n=125) vs 1.67% (n=120) placebo @ 12wk10 mg
NCT00960440 · Phase 3
5.69% (n=372) vs 0% (n=171) MTX @ 4.33wk10 mg BID
NCT01039688 · Phase 3
12.9% (n=372) vs 2.35% (n=171) MTX @ 8.67wk10 mg BID
NCT01039688 · Phase 3
17.47% (n=372) vs 4.68% (n=171) MTX @ 13wk10 mg BID
NCT01039688 · Phase 3
21.77% (n=372) vs 7.6% (n=171) MTX @ 26wk10 mg BID
NCT01039688 · Phase 3
23.66% (n=372) vs 9.94% (n=171) MTX @ 39wk10 mg BID
NCT01039688 · Phase 3
23.39% (n=372) vs 11.7% (n=171) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
24.19% (n=372) vs 12.87% (n=171) MTX @ 65wk10 mg BID
NCT01039688 · Phase 3
19.89% (n=372) vs 11.11% (n=171) MTX @ 78wk10 mg BID
NCT01039688 · Phase 3
21.42% (n=372) vs 8.77% (n=171) MTX @ 91wk10 mg BID
NCT01039688 · Phase 3
22.31% (n=372) vs 9.94% (n=171) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
ACR20 69.29% (n=241) @ 17.33wk5 mg
responder rate · % of participants
No placebo or comparator arm
NCT00814307 · Phase 3
show 76 more results
68.46% (n=241) @ 21.67wk5 mg
NCT00814307 · Phase 3
69.29% (n=241) @ 26wk5 mg
NCT00814307 · Phase 3
50.48% (n=311) @ 39wk5 mg
NCT00856544 · Phase 3
51.45% (n=311) @ 52wk5 mg
NCT00856544 · Phase 3
47.9% (n=309) @ 39wk5 mg
NCT00847613 · Phase 3
48.54% (n=309) @ 52wk5 mg
NCT00847613 · Phase 3
54.55% (n=132) @ 19.5wk5 mg
NCT00960440 · Phase 3
51.52% (n=132) @ 26wk5 mg
NCT00960440 · Phase 3
80.2% (n=381) @ 2wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
87.1% (n=381) @ 4wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90% (n=381) @ 8wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.9% (n=381) @ 12wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90.8% (n=381) @ 24wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
94.1% (n=381) @ 36wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
93.7% (n=381) @ 48wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.3% (n=381) @ 60wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.4% (n=381) @ 72wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
93.2% (n=381) @ 84wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.2% (n=381) @ 96wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.9% (n=381) @ 108wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.3% (n=381) @ 120wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.2% (n=381) @ 132wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
89.7% (n=381) @ 144wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.3% (n=381) @ 156wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.5% (n=381) @ 168wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.8% (n=381) @ 180wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.8% (n=381) @ 192wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.7% (n=381) @ 204wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
96.1% (n=381) @ 216wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.2% (n=381) @ 228wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
93.8% (n=381) @ 240wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.3% (n=381) @ 252wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
89.8% (n=381) @ 264wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
95.5% (n=381) @ 276wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=381) @ 288wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
73.86% (n=264) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
73.11% (n=264) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
69.01% (n=242) @ 17.33wk10 mg
NCT00814307 · Phase 3
69.83% (n=242) @ 21.67wk10 mg
NCT00814307 · Phase 3
71.07% (n=242) @ 26wk10 mg
NCT00814307 · Phase 3
62.14% (n=309) @ 39wk10 mg
NCT00856544 · Phase 3
56.63% (n=309) @ 52wk10 mg
NCT00856544 · Phase 3
62.46% (n=309) @ 39wk10 mg
NCT00847613 · Phase 3
56.96% (n=309) @ 52wk10 mg
NCT00847613 · Phase 3
47.37% (n=133) @ 19.5wk10 mg
NCT00960440 · Phase 3
54.89% (n=133) @ 26wk10 mg
NCT00960440 · Phase 3
68.6% (n=105) @ 2wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
70.5% (n=105) @ 4wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
72.4% (n=105) @ 8wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.1% (n=105) @ 12wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
85.6% (n=105) @ 24wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
87.3% (n=105) @ 36wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
88.2% (n=105) @ 48wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90.2% (n=105) @ 60wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.9% (n=105) @ 72wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
87% (n=105) @ 84wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92% (n=105) @ 96wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.9% (n=105) @ 108wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
88.8% (n=105) @ 120wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.8% (n=105) @ 132wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.8% (n=105) @ 144wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.9% (n=105) @ 156wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
82.9% (n=105) @ 168wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86% (n=105) @ 180wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
85.7% (n=105) @ 192wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90% (n=105) @ 204wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.6% (n=105) @ 216wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 228wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 240wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 252wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 264wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=105) @ 276wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80.83% (n=266) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
79.7% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
84.5% (n=103) @ 12wk*
NCT02281552 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
ACR50 37.34% (n=241) @ 17.33wk5 mg
responder rate · % of participants
No placebo or comparator arm
NCT00814307 · Phase 3
show 72 more results
39.42% (n=241) @ 21.67wk5 mg
NCT00814307 · Phase 3
41.91% (n=241) @ 26wk5 mg
NCT00814307 · Phase 3
31.51% (n=311) @ 39wk5 mg
NCT00856544 · Phase 3
33.44% (n=311) @ 52wk5 mg
NCT00856544 · Phase 3
28.79% (n=132) @ 19.5wk5 mg
NCT00960440 · Phase 3
37.12% (n=132) @ 26wk5 mg
NCT00960440 · Phase 3
59.5% (n=381) @ 2wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.8% (n=381) @ 4wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
70.4% (n=381) @ 8wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
70.8% (n=381) @ 12wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
76.2% (n=381) @ 24wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.3% (n=381) @ 36wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.3% (n=381) @ 48wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.1% (n=381) @ 60wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.8% (n=381) @ 72wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
78.6% (n=381) @ 84wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
78.3% (n=381) @ 96wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.9% (n=381) @ 108wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
76.4% (n=381) @ 120wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.2% (n=381) @ 132wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
78.1% (n=381) @ 144wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.5% (n=381) @ 156wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.3% (n=381) @ 168wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
82.2% (n=381) @ 180wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.7% (n=381) @ 192wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.4% (n=381) @ 204wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.8% (n=381) @ 216wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
76.5% (n=381) @ 228wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
83.1% (n=381) @ 240wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.2% (n=381) @ 252wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.7% (n=381) @ 264wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
81.8% (n=381) @ 276wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=381) @ 288wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
53.79% (n=264) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
55.3% (n=264) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
42.98% (n=242) @ 17.33wk10 mg
NCT00814307 · Phase 3
45.45% (n=242) @ 21.67wk10 mg
NCT00814307 · Phase 3
46.69% (n=242) @ 26wk10 mg
NCT00814307 · Phase 3
43.04% (n=309) @ 39wk10 mg
NCT00856544 · Phase 3
42.72% (n=309) @ 52wk10 mg
NCT00856544 · Phase 3
28.57% (n=133) @ 19.5wk10 mg
NCT00960440 · Phase 3
30.08% (n=133) @ 26wk10 mg
NCT00960440 · Phase 3
36.2% (n=105) @ 2wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.2% (n=105) @ 4wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
47.6% (n=105) @ 8wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
46.7% (n=105) @ 12wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62.5% (n=105) @ 24wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
56.9% (n=105) @ 36wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.8% (n=105) @ 48wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
66.7% (n=105) @ 60wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
74.7% (n=105) @ 72wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
64.1% (n=105) @ 84wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.9% (n=105) @ 96wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
72.6% (n=105) @ 108wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
68.8% (n=105) @ 120wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
72.2% (n=105) @ 132wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
69.7% (n=105) @ 144wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
65.8% (n=105) @ 156wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
67.1% (n=105) @ 168wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
71.9% (n=105) @ 180wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.9% (n=105) @ 192wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 204wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
53.8% (n=105) @ 216wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 228wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40% (n=105) @ 240wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40% (n=105) @ 252wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40% (n=105) @ 264wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=105) @ 276wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
66.54% (n=266) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
67.29% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
68% (n=103) @ 12wk*
NCT02281552 · Phase 3 · registry result, not featured evidence · converted to % from 70 participants as posted
ACR70 19.92% (n=241) @ 17.33wk5 mg
responder rate · % of participants
No placebo or comparator arm
NCT00814307 · Phase 3
show 76 more results
21.16% (n=241) @ 21.67wk5 mg
NCT00814307 · Phase 3
21.99% (n=241) @ 26wk5 mg
NCT00814307 · Phase 3
14.15% (n=311) @ 39wk5 mg
NCT00856544 · Phase 3
19.29% (n=311) @ 52wk5 mg
NCT00856544 · Phase 3
18.45% (n=309) @ 39wk5 mg
NCT00847613 · Phase 3
18.77% (n=309) @ 52wk5 mg
NCT00847613 · Phase 3
10.61% (n=132) @ 19.5wk5 mg
NCT00960440 · Phase 3
15.91% (n=132) @ 26wk5 mg
NCT00960440 · Phase 3
37% (n=381) @ 2wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
44.8% (n=381) @ 4wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
47.7% (n=381) @ 8wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
50% (n=381) @ 12wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
54.1% (n=381) @ 24wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
56.6% (n=381) @ 36wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.8% (n=381) @ 48wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.1% (n=381) @ 60wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.9% (n=381) @ 72wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.2% (n=381) @ 84wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.4% (n=381) @ 96wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.6% (n=381) @ 108wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62% (n=381) @ 120wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.8% (n=381) @ 132wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.2% (n=381) @ 144wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.6% (n=381) @ 156wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62.9% (n=381) @ 168wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.9% (n=381) @ 180wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.8% (n=381) @ 192wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62.4% (n=381) @ 204wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
69.7% (n=381) @ 216wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.2% (n=381) @ 228wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
69.2% (n=381) @ 240wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
73.8% (n=381) @ 252wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
71.2% (n=381) @ 264wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
68.2% (n=381) @ 276wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
66.7% (n=381) @ 288wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.61% (n=264) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
37.88% (n=264) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
26.03% (n=242) @ 17.33wk10 mg
NCT00814307 · Phase 3
28.51% (n=242) @ 21.67wk10 mg
NCT00814307 · Phase 3
29.34% (n=242) @ 26wk10 mg
NCT00814307 · Phase 3
25.24% (n=309) @ 39wk10 mg
NCT00856544 · Phase 3
25.57% (n=309) @ 52wk10 mg
NCT00856544 · Phase 3
28.48% (n=309) @ 39wk10 mg
NCT00847613 · Phase 3
27.51% (n=309) @ 52wk10 mg
NCT00847613 · Phase 3
12.78% (n=133) @ 19.5wk10 mg
NCT00960440 · Phase 3
15.79% (n=133) @ 26wk10 mg
NCT00960440 · Phase 3
19% (n=105) @ 2wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20.2% (n=105) @ 4wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
21% (n=105) @ 8wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
16.2% (n=105) @ 12wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
27.9% (n=105) @ 24wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
24.5% (n=105) @ 36wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
34.3% (n=105) @ 48wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.3% (n=105) @ 60wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
38.4% (n=105) @ 72wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.9% (n=105) @ 84wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
42.5% (n=105) @ 96wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
42.9% (n=105) @ 108wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.5% (n=105) @ 120wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40.5% (n=105) @ 132wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.5% (n=105) @ 144wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
41.1% (n=105) @ 156wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
41.4% (n=105) @ 168wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
47.4% (n=105) @ 180wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
42.9% (n=105) @ 192wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
56.7% (n=105) @ 204wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
30.8% (n=105) @ 216wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 228wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 240wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 252wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 264wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 276wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40.98% (n=266) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
42.86% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
31.1% (n=103) @ 12wk*
NCT02281552 · Phase 3 · registry result, not featured evidence · converted to % from 32 participants as posted
DAS28-ESR 4.78 vs 5.54 placebo score @ 13wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 113 more results
4.41 vs 5.32 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
4.14 vs 4.34 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
5.23 vs 5.93 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
4.64 vs 5.6 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
4.4 vs 4.61 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
4 vs 4.2 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
3.85 vs 3.95 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
5.12 vs 5.83 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
4.58 vs 5.57 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
4.34 vs 4.81 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
4.58 vs 5.56 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
5.18 vs 5.84 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
4.54 vs 5.35 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
4.21 vs 4.98 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
4.05 vs 4.61 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
3.84 vs 4.27 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
3.69 vs 4.23 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
3.59 vs 4.17 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
3.51 vs 4.05 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
3.49 vs 4.09 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
3.43 vs 3.99 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
5.61 vs 6.04 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.23 vs 5.7 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.9 vs 5.64 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.7 vs 5.56 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.5 vs 5.54 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.37 vs 5.39 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.25 vs 4.53 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.47 vs 4.47 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.33 vs 4.51 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.09 vs 5.46 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.48 vs 5.34 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.03 vs 5.49 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.49 vs 5.22 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.13 vs 5.07 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.55 vs 5.54 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
4.2 vs 5.32 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
3.84 vs 4.34 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
5.14 vs 5.93 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
4.66 vs 5.6 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
4.21 vs 4.61 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
4.08 vs 4.2 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
3.88 vs 3.95 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
4.84 vs 5.83 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
4.19 vs 5.57 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
3.9 vs 4.81 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
4.26 vs 5.56 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
4.7 vs 5.84 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
4.17 vs 5.35 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
3.94 vs 4.98 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
3.62 vs 4.61 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
3.53 vs 4.27 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
3.37 vs 4.23 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
3.32 vs 4.17 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
3.33 vs 4.05 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
3.33 vs 4.09 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
3.29 vs 3.99 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
5.2 vs 6.04 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.69 vs 5.7 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.33 vs 5.64 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.22 vs 5.56 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.93 vs 5.54 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.95 vs 5.39 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.86 vs 4.53 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.67 vs 4.47 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.62 vs 4.51 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.88 vs 5.46 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.28 vs 5.34 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.72 vs 5.49 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.13 vs 5.22 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.83 vs 5.07 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.2 vs 6.04 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.46 vs 5.7 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.02 vs 5.64 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8 vs 5.56 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.54 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.77 vs 5.39 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.63 vs 4.53 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.54 vs 4.47 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.61 vs 4.51 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.57 vs 6.04 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.1 vs 5.7 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.91 vs 5.64 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.89 vs 5.56 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.81 vs 5.54 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.78 vs 5.39 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.96 vs 4.53 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.08 vs 4.47 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.72 vs 4.51 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.33 vs 5.46 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.03 vs 5.34 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.54 vs 5.49 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4 vs 5.22 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.9 vs 5.07 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.92 vs 6.04 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.73 vs 5.7 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.36 vs 5.64 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.31 vs 5.56 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.22 vs 5.54 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.41 vs 5.39 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.39 vs 4.53 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.76 vs 4.47 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.87 vs 4.51 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.42 vs 5.46 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.29 vs 5.34 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5 vs 5.49 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.37 vs 5.22 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.07 vs 5.07 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
6.55 vs 6.32 placebo score @ 0.14wk
NCT00976599 · Phase 2 · registry result, not featured evidence
4.9 vs 6.03 placebo score @ 4wk
NCT00976599 · Phase 2 · registry result, not featured evidence
6.6 vs 6.44 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
4.33 vs 4.26 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.84 vs 3.81 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
DAS28-ESR 4.33 score @ 24wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 9 more results
3.82 score @ 48wk5 mg
NCT00856544 · Phase 3
4.12 score @ 39wk5 mg
NCT00847613 · Phase 3
4.09 score @ 52wk5 mg
NCT00847613 · Phase 3
3.99 score @ 24wk5 mg
NCT00960440 · Phase 3
4.01 score @ 24wk10 mg
NCT00814307 · Phase 3
3.5 score @ 48wk10 mg
NCT00856544 · Phase 3
3.84 score @ 39wk10 mg
NCT00847613 · Phase 3
3.79 score @ 52wk10 mg
NCT00847613 · Phase 3
3.7 score @ 24wk10 mg
NCT00960440 · Phase 3
DAS28-CRP 4.79 vs 5.3 placebo score @ 2wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 203 more results
4.41 vs 4.98 placebo score @ 4.33wk5 mg
NCT00814307 · Phase 3
4.02 vs 4.85 placebo score @ 8.67wk5 mg
NCT00814307 · Phase 3
3.89 vs 4.68 placebo score @ 13wk5 mg
NCT00814307 · Phase 3
4.41 vs 4.92 placebo score @ 2wk5 mg
NCT00856544 · Phase 3
4.08 vs 4.68 placebo score @ 4.33wk5 mg
NCT00856544 · Phase 3
3.7 vs 4.59 placebo score @ 8.67wk5 mg
NCT00856544 · Phase 3
3.62 vs 4.51 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
3.46 vs 3.92 placebo score @ 19.5wk5 mg
NCT00856544 · Phase 3
3.39 vs 3.6 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
4.26 vs 5.09 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
3.78 vs 4.83 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
3.51 vs 3.85 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
3.13 vs 3.46 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
3.05 vs 3.18 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
4.04 vs 4.73 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
3.62 vs 4.54 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
3.33 vs 3.79 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
4.46 vs 5.1 placebo score @ 2wk5 mg
NCT00960440 · Phase 3
4.14 vs 4.92 placebo score @ 4.33wk5 mg
NCT00960440 · Phase 3
3.74 vs 4.78 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
4.21 vs 4.96 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
3.67 vs 4.5 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
3.41 vs 4.14 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
3.21 vs 3.85 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
3.05 vs 3.49 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
2.92 vs 3.42 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
2.78 vs 3.38 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
2.7 vs 3.32 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
2.67 vs 3.33 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
2.65 vs 3.22 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
4.63 vs 5.24 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.36 vs 5.01 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.16 vs 4.92 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.01 vs 4.84 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8 vs 4.83 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.76 vs 4.83 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.55 vs 3.93 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.68 vs 3.97 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.64 vs 3.96 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.09 vs 4.61 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.46 vs 4.43 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.21 vs 4.56 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.77 vs 4.31 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.55 vs 4.15 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.26 vs 4.91 placebo score @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.03 vs 4.6 placebo score @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.68 vs 4.35 placebo score @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.54 vs 4.3 placebo score @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.57 vs 4.37 placebo score @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.19 vs 3.93 placebo score @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.09 vs 3.81 placebo score @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.03 vs 3.48 placebo score @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.42 vs 5.3 placebo score @ 2wk10 mg
NCT00814307 · Phase 3
3.99 vs 4.98 placebo score @ 4.33wk10 mg
NCT00814307 · Phase 3
3.64 vs 4.85 placebo score @ 8.67wk10 mg
NCT00814307 · Phase 3
3.59 vs 4.68 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
4.18 vs 4.92 placebo score @ 2wk10 mg
NCT00856544 · Phase 3
3.83 vs 4.68 placebo score @ 4.33wk10 mg
NCT00856544 · Phase 3
3.49 vs 4.59 placebo score @ 8.67wk10 mg
NCT00856544 · Phase 3
3.44 vs 4.51 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
3.15 vs 3.92 placebo score @ 19.5wk10 mg
NCT00856544 · Phase 3
3.09 vs 3.6 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
4.21 vs 5.09 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
3.77 vs 4.83 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
3.29 vs 3.85 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
3.2 vs 3.46 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
3 vs 3.18 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
3.84 vs 4.73 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
3.29 vs 4.54 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
2.96 vs 3.79 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
4.13 vs 5.1 placebo score @ 2wk10 mg
NCT00960440 · Phase 3
3.92 vs 4.92 placebo score @ 4.33wk10 mg
NCT00960440 · Phase 3
3.45 vs 4.78 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
3.77 vs 4.96 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
3.31 vs 4.5 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
3.05 vs 4.14 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
2.76 vs 3.85 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
2.69 vs 3.49 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
2.52 vs 3.42 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
2.5 vs 3.38 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
2.47 vs 3.32 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
2.48 vs 3.33 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
2.44 vs 3.22 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
4.16 vs 5.24 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.01 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.45 vs 4.92 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.37 vs 4.84 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 4.83 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.11 vs 4.83 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 3.93 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.85 vs 3.97 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.92 vs 3.96 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.74 vs 4.61 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.25 vs 4.43 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.8 vs 4.56 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.52 vs 4.31 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.14 vs 4.15 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.18 vs 4.91 placebo score @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.66 vs 4.6 placebo score @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.59 vs 4.35 placebo score @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.61 vs 4.3 placebo score @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.4 vs 4.37 placebo score @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.34 vs 3.93 placebo score @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.81 placebo score @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.15 vs 3.48 placebo score @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.28 vs 4.91 placebo score @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.99 vs 4.6 placebo score @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.94 vs 4.35 placebo score @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.72 vs 4.3 placebo score @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.61 vs 4.37 placebo score @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.93 placebo score @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.65 vs 3.93 placebo score @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.08 vs 3.81 placebo score @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.82 vs 3.81 placebo score @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.07 vs 3.48 placebo score @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.51 vs 3.48 placebo score @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.32 vs 5.24 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.01 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.34 vs 4.92 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.13 vs 4.84 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.05 vs 4.83 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 4.83 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.92 vs 3.93 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.93 vs 3.97 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.82 vs 3.96 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.18 vs 4.91 placebo score @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.75 vs 4.6 placebo score @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.6 vs 4.35 placebo score @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.38 vs 4.3 placebo score @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.28 vs 4.37 placebo score @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.12 vs 3.93 placebo score @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
2.94 vs 3.81 placebo score @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
2.91 vs 3.48 placebo score @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.6 vs 5.24 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.16 vs 5.01 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.02 vs 4.92 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4 vs 4.84 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.92 vs 4.83 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.96 vs 4.83 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.3 vs 3.93 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.26 vs 3.97 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.11 vs 3.96 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.3 vs 4.61 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.95 vs 4.43 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.63 vs 4.56 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.03 vs 4.31 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.14 vs 4.15 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.46 vs 4.91 placebo score @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.03 vs 4.6 placebo score @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.74 vs 4.35 placebo score @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.63 vs 4.3 placebo score @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.46 vs 4.37 placebo score @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.11 vs 3.93 placebo score @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.19 vs 3.93 placebo score @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.06 vs 3.81 placebo score @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.24 vs 3.81 placebo score @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.48 placebo score @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.08 vs 3.48 placebo score @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.96 vs 5.24 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.77 vs 5.01 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.42 vs 4.92 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.52 vs 4.84 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.37 vs 4.83 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.57 vs 4.83 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.63 vs 3.93 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.94 vs 3.97 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.11 vs 3.96 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.3 vs 4.61 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.23 vs 4.43 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.96 vs 4.56 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.43 vs 4.31 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.21 vs 4.15 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.88 vs 4.91 placebo score @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.45 vs 4.6 placebo score @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.32 vs 4.35 placebo score @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.21 vs 4.3 placebo score @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.98 vs 4.37 placebo score @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.59 vs 3.93 placebo score @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.33 vs 3.93 placebo score @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.48 vs 3.81 placebo score @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.83 vs 3.81 placebo score @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.39 vs 3.48 placebo score @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.88 vs 3.48 placebo score @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
5.57 vs 5.22 placebo score @ 0.14wk
NCT00976599 · Phase 2 · registry result, not featured evidence
4.06 vs 4.91 placebo score @ 4wk
NCT00976599 · Phase 2 · registry result, not featured evidence
5.38 vs 5.23 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.44 vs 3.33 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.06 vs 2.99 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
DAS28-CRP 3.65 score @ 17.33wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 17 more results
3.54 score @ 21.67wk5 mg
NCT00814307 · Phase 3
3.48 score @ 26wk5 mg
NCT00814307 · Phase 3
3.21 score @ 39wk5 mg
NCT00856544 · Phase 3
3.08 score @ 52wk5 mg
NCT00856544 · Phase 3
3.11 score @ 39wk5 mg
NCT00847613 · Phase 3
3.07 score @ 52wk5 mg
NCT00847613 · Phase 3
3.43 score @ 19.5wk5 mg
NCT00960440 · Phase 3
3.36 score @ 26wk5 mg
NCT00960440 · Phase 3
3.26 score @ 17.33wk10 mg
NCT00814307 · Phase 3
3.12 score @ 21.67wk10 mg
NCT00814307 · Phase 3
3.11 score @ 26wk10 mg
NCT00814307 · Phase 3
2.88 score @ 39wk10 mg
NCT00856544 · Phase 3
2.81 score @ 52wk10 mg
NCT00856544 · Phase 3
2.88 score @ 39wk10 mg
NCT00847613 · Phase 3
2.75 score @ 52wk10 mg
NCT00847613 · Phase 3
3.3 score @ 19.5wk10 mg
NCT00960440 · Phase 3
3.07 score @ 26wk10 mg
NCT00960440 · Phase 3
HAQ-DI 1.27 vs 1.43 placebo score @ 2wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 216 more results
1.18 vs 1.4 placebo score @ 4.33wk5 mg
NCT00814307 · Phase 3
1.05 vs 1.4 placebo score @ 8.67wk5 mg
NCT00814307 · Phase 3
1.05 vs 1.35 placebo score @ 13wk5 mg
NCT00814307 · Phase 3
1.24 vs 1.28 placebo score @ 2wk5 mg
NCT00856544 · Phase 3
1.12 vs 1.2 placebo score @ 4.33wk5 mg
NCT00856544 · Phase 3
1.03 vs 1.2 placebo score @ 8.67wk5 mg
NCT00856544 · Phase 3
0.98 vs 1.16 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
0.97 vs 0.95 placebo score @ 19.5wk5 mg
NCT00856544 · Phase 3
0.91 vs 0.93 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
1.15 vs 1.32 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
1 vs 1.25 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
0.92 vs 1.15 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
0.86 vs 0.97 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
0.83 vs 0.9 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
1.16 vs 1.25 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
1 vs 1.19 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
0.94 vs 1.09 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
1.38 vs 1.49 placebo score @ 2wk5 mg
NCT00960440 · Phase 3
1.37 vs 1.38 placebo score @ 4.33wk5 mg
NCT00960440 · Phase 3
1.2 vs 1.44 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
1.05 vs 1.3 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
0.89 vs 1.17 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
0.78 vs 1.03 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
0.69 vs 0.92 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
0.66 vs 0.83 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
0.64 vs 0.79 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
0.59 vs 0.83 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
0.58 vs 0.74 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
0.59 vs 0.76 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
0.58 vs 0.77 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
1.22 vs 1.49 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.14 vs 1.38 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.14 vs 1.31 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.99 vs 1.24 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.94 vs 1.24 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.94 vs 1.24 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.91 vs 1.28 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.96 vs 1.3 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.95 vs 1.2 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.25 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.88 vs 1.18 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.79 vs 1.07 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.72 vs 1.21 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.56 vs 1.13 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.2 vs 1.15 placebo score @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.13 vs 1.14 placebo score @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.03 vs 1.07 placebo score @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.06 vs 1.05 placebo score @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.94 vs 1.08 placebo score @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 0.8 placebo score @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.78 vs 0.73 placebo score @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.78 vs 0.74 placebo score @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.46 vs 1.63 placebo score @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.32 vs 1.53 placebo score @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.17 vs 1.54 placebo score @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.12 vs 1.47 placebo score @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.3 vs 1.52 placebo score @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.21 vs 1.43 placebo score @ 2wk10 mg
NCT00814307 · Phase 3
1.09 vs 1.4 placebo score @ 4.33wk10 mg
NCT00814307 · Phase 3
0.97 vs 1.4 placebo score @ 8.67wk10 mg
NCT00814307 · Phase 3
0.97 vs 1.35 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
1.14 vs 1.28 placebo score @ 2wk10 mg
NCT00856544 · Phase 3
1.01 vs 1.2 placebo score @ 4.33wk10 mg
NCT00856544 · Phase 3
0.93 vs 1.2 placebo score @ 8.67wk10 mg
NCT00856544 · Phase 3
0.88 vs 1.16 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
0.84 vs 0.95 placebo score @ 19.5wk10 mg
NCT00856544 · Phase 3
0.81 vs 0.93 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
1.11 vs 1.32 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
0.94 vs 1.25 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
0.89 vs 1.15 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
0.85 vs 0.97 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
0.81 vs 0.9 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
1.02 vs 1.25 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
0.84 vs 1.19 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
0.79 vs 1.09 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
1.28 vs 1.49 placebo score @ 2wk10 mg
NCT00960440 · Phase 3
1.19 vs 1.38 placebo score @ 4.33wk10 mg
NCT00960440 · Phase 3
1.1 vs 1.44 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
0.89 vs 1.3 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
0.74 vs 1.17 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
0.67 vs 1.03 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
0.57 vs 0.92 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
0.56 vs 0.83 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
0.51 vs 0.79 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
0.51 vs 0.83 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
0.48 vs 0.74 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
0.49 vs 0.76 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
0.48 vs 0.77 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
1.22 vs 1.49 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.04 vs 1.38 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1 vs 1.31 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.97 vs 1.24 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.86 vs 1.24 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.24 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.85 vs 1.28 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.8 vs 1.3 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.2 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.85 vs 1.25 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.79 vs 1.18 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.77 vs 1.07 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.64 vs 1.21 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.59 vs 1.13 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.16 vs 1.15 placebo score @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.08 vs 1.14 placebo score @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.02 vs 1.07 placebo score @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.89 vs 1.05 placebo score @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.95 vs 1.08 placebo score @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.91 vs 0.8 placebo score @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.84 vs 0.73 placebo score @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.85 vs 0.74 placebo score @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.19 vs 1.63 placebo score @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.06 vs 1.53 placebo score @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.92 vs 1.54 placebo score @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.86 vs 1.47 placebo score @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.92 vs 1.52 placebo score @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.23 vs 1.15 placebo score @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.14 vs 1.14 placebo score @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 1.07 placebo score @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.98 vs 1.05 placebo score @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.9 vs 1.08 placebo score @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.81 vs 0.8 placebo score @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.36 vs 0.8 placebo score @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.75 vs 0.73 placebo score @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.42 vs 0.73 placebo score @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.72 vs 0.74 placebo score @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.34 vs 0.74 placebo score @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.26 vs 1.49 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.08 vs 1.38 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.93 vs 1.31 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.86 vs 1.24 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.24 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.78 vs 1.24 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.73 vs 1.28 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.71 vs 1.3 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.79 vs 1.2 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.15 vs 1.15 placebo score @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.12 vs 1.14 placebo score @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 1.07 placebo score @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.98 vs 1.05 placebo score @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.96 vs 1.08 placebo score @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.97 vs 0.8 placebo score @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 0.73 placebo score @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.88 vs 0.74 placebo score @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.37 vs 1.63 placebo score @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.17 vs 1.53 placebo score @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.07 vs 1.54 placebo score @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.95 vs 1.47 placebo score @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.06 vs 1.52 placebo score @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.28 vs 1.49 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.23 vs 1.38 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.24 vs 1.31 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.12 vs 1.24 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.2 vs 1.24 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.09 vs 1.24 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.04 vs 1.28 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1 vs 1.3 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.96 vs 1.2 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.23 vs 1.25 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.12 vs 1.18 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.04 vs 1.07 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.96 vs 1.21 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.81 vs 1.13 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.14 vs 1.15 placebo score @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.03 vs 1.14 placebo score @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.96 vs 1.07 placebo score @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.93 vs 1.05 placebo score @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 1.08 placebo score @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.82 vs 0.8 placebo score @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.18 vs 0.8 placebo score @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.77 vs 0.73 placebo score @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.13 vs 0.73 placebo score @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.85 vs 0.74 placebo score @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 0.74 placebo score @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.45 vs 1.49 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.45 vs 1.38 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.3 vs 1.31 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.29 vs 1.24 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.25 vs 1.24 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.28 vs 1.24 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.02 vs 1.28 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.3 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.02 vs 1.2 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.25 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.04 vs 1.18 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.94 vs 1.07 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.8 vs 1.21 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.78 vs 1.13 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.41 vs 1.15 placebo score @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.32 vs 1.14 placebo score @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.23 vs 1.07 placebo score @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.22 vs 1.05 placebo score @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.19 vs 1.08 placebo score @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 0.8 placebo score @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.42 vs 0.8 placebo score @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.95 vs 0.73 placebo score @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.33 vs 0.73 placebo score @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.99 vs 0.74 placebo score @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.38 vs 0.74 placebo score @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.54 vs 1.46 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
0.88 vs 0.88 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
0.74 vs 0.92 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
HAQ-DI 0.97 score @ 17.33wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 96 more results
0.95 score @ 21.67wk5 mg
NCT00814307 · Phase 3
0.94 score @ 26wk5 mg
NCT00814307 · Phase 3
0.89 score @ 39wk5 mg
NCT00856544 · Phase 3
0.86 score @ 52wk5 mg
NCT00856544 · Phase 3
0.91 score @ 39wk5 mg
NCT00847613 · Phase 3
0.9 score @ 52wk5 mg
NCT00847613 · Phase 3
1.19 score @ 19.5wk5 mg
NCT00960440 · Phase 3
1.1 score @ 26wk5 mg
NCT00960440 · Phase 3
-0.57 score @ 4.33wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 8.67wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 13wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 26wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 39wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 52wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 65wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 78wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 91wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 104wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.62 score @ 117wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 130wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 143wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.63 score @ 156wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 169wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 182wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 195wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 208wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 221wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 234wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 247wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 260wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 273wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 286wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.55 score @ 299wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 312wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 325wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 338wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.55 score @ 351wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 364wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 377wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.52 score @ 390wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.52 score @ 403wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 416wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 429wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 442wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 455wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.89 score @ 468wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-1.29 score @ 481wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.13 score @ 494wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.88 score @ 17.33wk10 mg
NCT00814307 · Phase 3
0.87 score @ 21.67wk10 mg
NCT00814307 · Phase 3
0.86 score @ 26wk10 mg
NCT00814307 · Phase 3
0.71 score @ 39wk10 mg
NCT00856544 · Phase 3
0.73 score @ 52wk10 mg
NCT00856544 · Phase 3
0.75 score @ 39wk10 mg
NCT00847613 · Phase 3
0.76 score @ 52wk10 mg
NCT00847613 · Phase 3
1.1 score @ 19.5wk10 mg
NCT00960440 · Phase 3
1.02 score @ 26wk10 mg
NCT00960440 · Phase 3
-0.61 score @ 4.33wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 8.67wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 13wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 26wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 39wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 52wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 65wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 78wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 91wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 104wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 117wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 130wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 143wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 156wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 169wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 182wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 195wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 208wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.63 score @ 221wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 234wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 247wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 260wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 273wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 286wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 299wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.62 score @ 312wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 325wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 338wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 351wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.56 score @ 364wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 377wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 390wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.5 score @ 403wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.48 score @ 416wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.44 score @ 429wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.29 score @ 442wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.5 score @ 455wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.13 score @ 468wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.25 score @ 481wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
Patient Pain VAS 45.92 vs 55.61 placebo mm @ 2wk5 mg
absolute value · mm
NCT00814307 · Phase 3
show 210 more results
40.68 vs 52.47 placebo mm @ 4.33wk5 mg
NCT00814307 · Phase 3
36.39 vs 52.38 placebo mm @ 8.67wk5 mg
NCT00814307 · Phase 3
34.93 vs 49.84 placebo mm @ 13wk5 mg
NCT00814307 · Phase 3
46.81 vs 51.01 placebo mm @ 2wk5 mg
NCT00856544 · Phase 3
40.17 vs 45.69 placebo mm @ 4.33wk5 mg
NCT00856544 · Phase 3
36.4 vs 47.3 placebo mm @ 8.67wk5 mg
NCT00856544 · Phase 3
34.92 vs 46.59 placebo mm @ 13wk5 mg
NCT00856544 · Phase 3
34.43 vs 40.23 placebo mm @ 19.5wk5 mg
NCT00856544 · Phase 3
31.07 vs 34.19 placebo mm @ 26wk5 mg
NCT00856544 · Phase 3
39.71 vs 49.92 placebo mm @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
32.98 vs 48.53 placebo mm @ 13wk5 mg twice daily
NCT00853385 · Phase 3
30.4 vs 35.04 placebo mm @ 26wk5 mg twice daily
NCT00853385 · Phase 3
27.04 vs 32.7 Adalimumab mm @ 39wk5 mg twice daily
NCT00853385 · Phase 3
26.99 vs 27.94 Adalimumab mm @ 52wk5 mg twice daily
NCT00853385 · Phase 3
41.61 vs 49.22 placebo mm @ 4.33wk5 mg
NCT00847613 · Phase 3
34.47 vs 46.96 placebo mm @ 13wk5 mg
NCT00847613 · Phase 3
32.79 vs 36.76 placebo mm @ 26wk5 mg
NCT00847613 · Phase 3
36.62 vs 46.34 MTX mm @ 4.33wk5 mg BID
NCT01039688 · Phase 3
31.97 vs 39.74 MTX mm @ 8.67wk5 mg BID
NCT01039688 · Phase 3
29.41 vs 36.83 MTX mm @ 13wk5 mg BID
NCT01039688 · Phase 3
27.07 vs 30.94 MTX mm @ 26wk5 mg BID
NCT01039688 · Phase 3
26.11 vs 31.22 MTX mm @ 39wk5 mg BID
NCT01039688 · Phase 3
26.09 vs 29.91 MTX mm @ 52wk5 mg BID
NCT01039688 · Phase 3
24.25 vs 29.85 MTX mm @ 65wk5 mg BID
NCT01039688 · Phase 3
23.66 vs 27.81 MTX mm @ 78wk5 mg BID
NCT01039688 · Phase 3
23.3 vs 29.18 MTX mm @ 91wk5 mg BID
NCT01039688 · Phase 3
23.03 vs 27.52 MTX mm @ 104wk5 mg BID
NCT01039688 · Phase 3
47.1 vs 55.26 placebo mm @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.65 vs 50.89 placebo mm @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.24 vs 49.63 placebo mm @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.91 vs 47.26 placebo mm @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.67 vs 44.96 placebo mm @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.7 vs 43.93 placebo mm @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.39 vs 37.55 placebo mm @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.13 vs 36.95 placebo mm @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.81 vs 31.35 placebo mm @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
40.19 vs 49.36 placebo mm @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
33.19 vs 48.58 placebo mm @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
25.19 vs 49.72 placebo mm @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
22.59 vs 48.88 placebo mm @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.58 vs 44.96 placebo mm @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
44.35 vs 46.91 placebo mm @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
40.03 vs 42.02 placebo mm @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.33 vs 42.21 placebo mm @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.55 vs 41.34 placebo mm @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.88 vs 41.02 placebo mm @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.98 vs 30.08 placebo mm @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
25.91 vs 25.08 placebo mm @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.45 vs 27.14 placebo mm @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
51.76 vs 62.51 placebo mm @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
45.59 vs 60.65 placebo mm @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.77 vs 56.96 placebo mm @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
35.57 vs 52.75 placebo mm @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
42.44 vs 49.06 placebo mm @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
42.13 vs 55.61 placebo mm @ 2wk10 mg
NCT00814307 · Phase 3
36.86 vs 52.47 placebo mm @ 4.33wk10 mg
NCT00814307 · Phase 3
31.66 vs 52.38 placebo mm @ 8.67wk10 mg
NCT00814307 · Phase 3
31.37 vs 49.84 placebo mm @ 13wk10 mg
NCT00814307 · Phase 3
41.85 vs 51.01 placebo mm @ 2wk10 mg
NCT00856544 · Phase 3
37.08 vs 45.69 placebo mm @ 4.33wk10 mg
NCT00856544 · Phase 3
32.84 vs 47.3 placebo mm @ 8.67wk10 mg
NCT00856544 · Phase 3
32.96 vs 46.59 placebo mm @ 13wk10 mg
NCT00856544 · Phase 3
32.62 vs 40.23 placebo mm @ 19.5wk10 mg
NCT00856544 · Phase 3
29.94 vs 34.19 placebo mm @ 26wk10 mg
NCT00856544 · Phase 3
36.77 vs 49.92 placebo mm @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
31.27 vs 48.53 placebo mm @ 13wk10 mg twice daily
NCT00853385 · Phase 3
28.36 vs 35.04 placebo mm @ 26wk10 mg twice daily
NCT00853385 · Phase 3
27.99 vs 32.7 Adalimumab mm @ 39wk10 mg twice daily
NCT00853385 · Phase 3
24.55 vs 27.94 Adalimumab mm @ 52wk10 mg twice daily
NCT00853385 · Phase 3
33.91 vs 49.22 placebo mm @ 4.33wk10 mg
NCT00847613 · Phase 3
29.23 vs 46.96 placebo mm @ 13wk10 mg
NCT00847613 · Phase 3
29.05 vs 36.76 placebo mm @ 26wk10 mg
NCT00847613 · Phase 3
32.78 vs 46.34 MTX mm @ 4.33wk10 mg BID
NCT01039688 · Phase 3
30.33 vs 39.74 MTX mm @ 8.67wk10 mg BID
NCT01039688 · Phase 3
27.07 vs 36.83 MTX mm @ 13wk10 mg BID
NCT01039688 · Phase 3
24.22 vs 30.94 MTX mm @ 26wk10 mg BID
NCT01039688 · Phase 3
23.76 vs 31.22 MTX mm @ 39wk10 mg BID
NCT01039688 · Phase 3
22.64 vs 29.91 MTX mm @ 52wk10 mg BID
NCT01039688 · Phase 3
23.72 vs 29.85 MTX mm @ 65wk10 mg BID
NCT01039688 · Phase 3
22.72 vs 27.81 MTX mm @ 78wk10 mg BID
NCT01039688 · Phase 3
22.85 vs 29.18 MTX mm @ 91wk10 mg BID
NCT01039688 · Phase 3
21.09 vs 27.52 MTX mm @ 104wk10 mg BID
NCT01039688 · Phase 3
43.9 vs 55.26 placebo mm @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.28 vs 50.89 placebo mm @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.68 vs 49.63 placebo mm @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.05 vs 47.26 placebo mm @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.11 vs 44.96 placebo mm @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.14 vs 43.93 placebo mm @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.05 vs 37.55 placebo mm @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.43 vs 36.95 placebo mm @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
22.85 vs 31.35 placebo mm @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
37.08 vs 49.36 placebo mm @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
31.4 vs 48.58 placebo mm @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.46 vs 49.72 placebo mm @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
19.43 vs 48.88 placebo mm @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
16.9 vs 44.96 placebo mm @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
41.26 vs 46.91 placebo mm @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.34 vs 42.02 placebo mm @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.38 vs 42.21 placebo mm @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.6 vs 41.34 placebo mm @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.78 vs 41.02 placebo mm @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.33 vs 30.08 placebo mm @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.66 vs 25.08 placebo mm @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.65 vs 27.14 placebo mm @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
37.71 vs 62.51 placebo mm @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.83 vs 60.65 placebo mm @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
26.76 vs 56.96 placebo mm @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
23.39 vs 52.75 placebo mm @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
31.12 vs 49.06 placebo mm @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.57 vs 46.91 placebo mm @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
34.39 vs 42.02 placebo mm @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.65 vs 42.21 placebo mm @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.16 vs 41.34 placebo mm @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.09 vs 41.02 placebo mm @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.56 vs 30.08 placebo mm @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
51.25 vs 30.08 placebo mm @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.58 vs 25.08 placebo mm @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
43.92 vs 25.08 placebo mm @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
19.92 vs 27.14 placebo mm @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.33 vs 27.14 placebo mm @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
41.28 vs 55.26 placebo mm @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.69 vs 50.89 placebo mm @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.24 vs 49.63 placebo mm @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
26.74 vs 47.26 placebo mm @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.38 vs 44.96 placebo mm @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.26 vs 43.93 placebo mm @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.24 vs 37.55 placebo mm @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.21 vs 36.95 placebo mm @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
25.31 vs 31.35 placebo mm @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
37.82 vs 46.91 placebo mm @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.81 vs 42.02 placebo mm @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
32.97 vs 42.21 placebo mm @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.26 vs 41.34 placebo mm @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
31.48 vs 41.02 placebo mm @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
27.07 vs 30.08 placebo mm @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.69 vs 25.08 placebo mm @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.47 vs 27.14 placebo mm @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
46.11 vs 62.51 placebo mm @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.14 vs 60.65 placebo mm @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.42 vs 56.96 placebo mm @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
28.35 vs 52.75 placebo mm @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.62 vs 49.06 placebo mm @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
45.25 vs 55.26 placebo mm @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.91 vs 50.89 placebo mm @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.75 vs 49.63 placebo mm @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.21 vs 47.26 placebo mm @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.24 vs 44.96 placebo mm @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.3 vs 43.93 placebo mm @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.97 vs 37.55 placebo mm @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.66 vs 36.95 placebo mm @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.62 vs 31.35 placebo mm @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.5 vs 49.36 placebo mm @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
40.52 vs 48.58 placebo mm @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
34.88 vs 49.72 placebo mm @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.04 vs 48.88 placebo mm @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
27.17 vs 44.96 placebo mm @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
43.33 vs 46.91 placebo mm @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
37.83 vs 42.02 placebo mm @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.75 vs 42.21 placebo mm @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
28.81 vs 41.34 placebo mm @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
30.9 vs 41.02 placebo mm @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.67 vs 30.08 placebo mm @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.31 vs 30.08 placebo mm @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
26.63 vs 25.08 placebo mm @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
42.31 vs 25.08 placebo mm @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.98 vs 27.14 placebo mm @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.62 vs 27.14 placebo mm @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
53.76 vs 55.26 placebo mm @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
51.72 vs 50.89 placebo mm @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.31 vs 49.63 placebo mm @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.28 vs 47.26 placebo mm @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.7 vs 44.96 placebo mm @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.25 vs 43.93 placebo mm @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35 vs 37.55 placebo mm @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.67 vs 36.95 placebo mm @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
44.13 vs 31.35 placebo mm @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.36 vs 49.36 placebo mm @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
45.11 vs 48.58 placebo mm @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.44 vs 49.72 placebo mm @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
32.65 vs 48.88 placebo mm @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
32.19 vs 44.96 placebo mm @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
49.53 vs 46.91 placebo mm @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
45.57 vs 42.02 placebo mm @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.74 vs 42.21 placebo mm @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.97 vs 41.34 placebo mm @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
35.92 vs 41.02 placebo mm @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
27.83 vs 30.08 placebo mm @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
40.38 vs 30.08 placebo mm @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.28 vs 25.08 placebo mm @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.71 vs 25.08 placebo mm @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.53 vs 27.14 placebo mm @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.15 vs 27.14 placebo mm @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
65.66 vs 64.41 placebo mm @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
30.18 vs 31.26 placebo mm @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
25.72 vs 29.09 placebo mm @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
Patient Pain VAS 33.18 mm @ 17.33wk5 mg
absolute value · mm
No placebo or comparator arm
NCT00814307 · Phase 3
show 13 more results
32.63 mm @ 21.67wk5 mg
NCT00814307 · Phase 3
32.6 mm @ 26wk5 mg
NCT00814307 · Phase 3
30.78 mm @ 39wk5 mg
NCT00856544 · Phase 3
30.18 mm @ 52wk5 mg
NCT00856544 · Phase 3
31.59 mm @ 39wk5 mg
NCT00847613 · Phase 3
30.54 mm @ 52wk5 mg
NCT00847613 · Phase 3
29.7 mm @ 17.33wk10 mg
NCT00814307 · Phase 3
29.1 mm @ 21.67wk10 mg
NCT00814307 · Phase 3
27.89 mm @ 26wk10 mg
NCT00814307 · Phase 3
27.13 mm @ 39wk10 mg
NCT00856544 · Phase 3
25.43 mm @ 52wk10 mg
NCT00856544 · Phase 3
27.14 mm @ 39wk10 mg
NCT00847613 · Phase 3
27.45 mm @ 52wk10 mg
NCT00847613 · Phase 3

+ 671 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · tofacitinib's landscape